Hospira 10-Q 6 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 04, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'HOSPIRA INC	'
Entity Central Index Key	'0001274057	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	165,875,236
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net sales	$1,008.20	$994	$2,918.40	$2,993.20
Cost of products sold	718	779.7	2,159.50	2,195.40
Restructuring and impairment	9.8	9.4	21.4	41.6
Research and development	69.9	66.2	218.1	218.9
Selling, general and administrative	180.7	155.2	556	509.3
Total operating costs and expenses	978.4	1,010.50	2,955	2,965.20
Income (Loss) From Operations	29.8	-16.5	-36.6	28
Interest expense	23.3	21.1	62.8	64.3
Other expense, net	39	2.8	51.3	12.8
Loss Before Income Taxes	-32.5	-40.4	-150.7	-49.1
Income tax benefit	-31.7	-34.7	-96.2	-61
Equity income from affiliates, net	-2.7	-6.9	-12.7	-27
Net Income (Loss)	1.9	1.2	-41.8	38.9
Earnings (Loss) Per Common Share:	'	'	'	'
Basic (in dollars per share)	$0.01	$0.01	($0.25)	$0.24
Diluted (in dollars per share)	$0.01	$0.01	($0.25)	$0.23
Weighted Average Common Shares Outstanding:	'	'	'	'
Basic (in shares)	165.7	165.1	165.5	165
Diluted (in shares)	167	165.9	165.5	166
Comprehensive (Loss) Income :	'	'	'	'
Foreign currency translation adjustments, net of taxes $0.0 million	-5.5	39.5	-139.3	9.7
Pension liability adjustments, net of taxes $(1.9) million and $(1.5) million for the three months ended September 30, 2013 and 2012, respectively, and $(5.6) million and $(6.0) million for the nine months ended September 30, 2013 and 2012, respectively.	2.9	3.4	9	9.8
Losses on marketable equity securities, net of taxes $0.0 million	0	-0.3	0	-1.3
(Losses) gains on cash flow hedges, net of taxes $1.3 million and $0.0 million for the three months ended September 30, 2013 and 2012, respectively, and $1.4 million and $0.0 million for the nine months ended September 30, 2013 and 2012, respectively.	-2.3	0	-2.4	0.1
Other comprehensive (loss) income	-4.9	42.6	-132.7	18.3
Net Income (Loss)	1.9	1.2	-41.8	38.9
Comprehensive (Loss) Income	($3)	$43.80	($174.50)	$57.20

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Income and Comprehensive Income (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement of Other Comprehensive Income [Abstract]	'	'	'	'
Foreign currency translation adjustments, taxes	$0	$0	$0	$0
Pension liability adjustments, taxes	-1.9	-1.5	-5.6	-6
Unrealized (losses) gains on marketable equity securities, taxes	0	0	0	0
Reclassification of gains on terminated cash flow hedges, taxes	$1.30	$0	$1.40	$0

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash Flow From Operating Activities:	'	'
Net (loss) income	($41.80)	$38.90
Adjustments to reconcile net (loss) income to net cash from operating activities-	'	'
Depreciation	128.9	122.2
Amortization of intangible assets	63.8	62.6
Loss on early debt extinguishment	33.4	0
Stock-based compensation expense	31.1	29.9
Undistributed equity income from affiliates	-12.7	-27
Distributions received from equity affiliates	30.1	0
Deferred income taxes	-119.7	-47
Impairments and other asset charges	73.1	58.3
Gains on disposition of assets	-0.9	-5.9
Changes in assets and liabilities-	'	'
Trade receivables	11.2	55.4
Inventories	-144.3	9.5
Prepaid expenses and other assets	-48.7	-39.9
Trade accounts payable	-11.3	31.1
Other liabilities	60	114.5
Other, net	9.3	1.8
Net Cash Provided by Operating Activities	61.5	404.4
Cash Flow From Investing Activities:	'	'
Capital expenditures (including instruments placed with or leased to customers)	-248.5	-201.8
Other payments to acquire business	0	-15
Purchases of intangibles and other investments	-12.2	-9.6
Proceeds from disposition of businesses and assets	1.4	9.6
Net Cash Used in Investing Activities	-259.3	-216.8
Cash Flow From Financing Activities:	'	'
Issuance of long-term debt, net of fees paid	691.8	0
Repayment of long-term debt	-650	0
Payment on early debt extinguishment	-39.8	0
Other borrowings, net	56	45.8
Excess tax benefit from stock-based compensation arrangements	1.1	2.1
Proceeds from stock options exercised	13	6.9
Net Cash Provided by Financing Activities	72.1	54.8
Effect of exchange rate changes on cash and cash equivalents	-14.6	1.3
Net change in cash and cash equivalents	-140.3	243.7
Cash and cash equivalents at beginning of period	772.1	597.5
Cash and cash equivalents at end of period	631.8	841.2
Cash paid during the period-	'	'
Interest	93.7	65.8
Income taxes, net of refunds	55.7	0.5
Accrued capital expenditures	$12.20	$8

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$631.80	$772.10
Trade receivables, less allowances of $14.4 in 2013 and $12.7 in 2012	630.1	646.9
Inventories, net	1,071.40	997.8
Deferred income taxes	188.8	214.4
Prepaid expenses	85.9	53.9
Other receivables	101.7	75.3
Total Current Assets	2,709.70	2,760.40
Property and equipment, net	1,487	1,445.10
Intangible assets, net	192	266.8
Goodwill	1,058.60	1,079.10
Deferred income taxes	399.7	296.8
Investments	35.8	71.8
Other assets	149.4	168.6
Total Assets	6,032.20	6,088.60
Current Liabilities:	'	'
Short-term borrowings	74.1	28.9
Trade accounts payable	255.4	276
Salaries, wages and commissions	166.4	144
Other accrued liabilities	518.1	580.3
Total Current Liabilities	1,014	1,029.20
Long-term debt	1,747.40	1,706.80
Deferred income taxes	3.6	4.4
Post-retirement obligations and other long-term liabilities	356	306.5
Commitments and Contingencies	'	'
Total Shareholders' Equity	2,911.20	3,041.70
Total Liabilities and Shareholders' Equity	$6,032.20	$6,088.60

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Statement of Financial Position [Abstract]	'	'
Trade receivables, allowances	$14.40	$12.70

Condensed_Consolidated_Stateme3

Condensed Consolidated Statement of Changes in Shareholders' Equity (USD $)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss
In Millions, unless otherwise specified
Balances at Dec. 31, 2012	$3,041.70	$1.80	($599.80)	$1,790.80	$1,932.10	($83.20)
Balances (in shares) at Dec. 31, 2012	'	165.3	'	'	'	'
Increase (Decrease) in Shareholders' Equity	'	'	'	'	'	'
Net loss	-41.8	0	0	0	-41.8	0
Other comprehensive loss	-132.7	0	0	0	0	-132.7
Changes in shareholders' equity related to incentive stock programs	44	0	0	44	0	0
Changes in shareholders' equity related to insentive stock programs (in shares)	'	0.6	'	'	'	'
Balances at Sep. 30, 2013	$2,911.20	$1.80	($599.80)	$1,834.80	$1,890.30	($215.90)
Balances (in shares) at Sep. 30, 2013	'	165.9	'	'	'	'

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Basis of Presentation and Significant Accounting Policies	'
	Basis of Presentation and Significant Accounting Policies
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for interim reporting and, therefore, do not include all information and footnote disclosures normally included in audited financial statements in conformity with generally accepted accounting principles in the United States. However, in the opinion of management, all adjustments, consisting of normal recurring adjustments, unless otherwise noted herein, necessary to present fairly the results of operations, financial position and cash flows have been made. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Hospira, Inc. (“Hospira”) Annual Report on Form 10-K for the year ended December 31, 2012 (the “2012 Form 10-K”). The results of operations for any interim period are not necessarily indicative of the results of operations to be expected for the full year.
	Recently Issued Accounting Standards
	In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-04, “Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date” (“ASU 2013-04”). ASU 2013-04 provides guidance for the recognition, measurement and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of ASU 2013-04 is fixed at the reporting date. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors as well as any additional amount the reporting entity expects to pay on behalf of its co-obligors. ASU 2013-04 also requires an entity to disclose the nature and amount of those obligations. ASU 2013-04 is effective for reporting periods beginning after December 15, 2013, with early adoption permitted. Retrospective application is required. Hospira is currently evaluating the impact of ASU 2013-04 on its condensed consolidated financial statements and related disclosures.
	In March 2013, the FASB issued ASU 2013-05, “Parent's Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity” (“ASU 2013-05”). ASU 2013-05 clarifies the applicable guidance for the release of cumulative translation adjustments into net income when a reporting entity either sells a part or all of its investment in a foreign entity or ceases to have a controlling financial interest in a subsidiary or group of assets that constitute a business within a foreign entity. ASU 2013-05 is effective prospectively for reporting periods beginning after December 15, 2013, with early adoption permitted. Hospira is currently evaluating the impact of ASU 2013-05 on its condensed consolidated financial statements and related disclosures.
	In July 2013, the FASB issued ASU 2013-11, "Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists" ("ASU 2013-11"). ASU 2013-11 requires, unless certain conditions exists, an unrecognized tax benefit, or a portion of an unrecognized tax benefit, to be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, similar tax loss, or a tax credit carryforward. ASU 2013-11 is effective prospectively for reporting periods beginning after December 15, 2013, with early adoption permitted. Retrospective application is permitted. Hospira is currently evaluating the impact of ASU 2013-11 on its condensed consolidated financial statements and related disclosures.
	Adoption of New Accounting Standards
	In December 2011, the FASB issued ASU 2011-11, “Disclosures About Offsetting Assets and Liabilities” (“ASU 2011-11”). The amendments in ASU 2011-11 require disclosures about offsetting and related arrangements to enable users of financial statements to understand the effect of those arrangements on an entity’s financial position. The amendments affect financial instruments and derivative instruments that are either (i) offset in accordance with current literature or (ii) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with current literature. In January 2013, the FASB issued ASU 2013-01, "Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities" ("ASU 2013-01") to clarify the scope of ASU 2011-11. ASU 2011-11, as amended by ASU 2013-01, is effective for fiscal years and interim periods within those years, beginning on or after January 1, 2013. There was no material impact to Hospira’s condensed consolidated financial position, results of operations or cash flows upon adoption of this guidance.
	In February 2013, the FASB issued ASU 2013-02, “Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income” (“ASU 2013-02”). ASU 2013-02 requires an entity to present, either on the face of the financial statements or in the notes, the effects of significant amounts reclassified out of accumulated other comprehensive loss on the respective line items of net income (loss) and to cross-reference to other required disclosures, where applicable. ASU 2013-02 is effective prospectively for reporting periods beginning after December 15, 2012, with early adoption permitted. There was no material impact to Hospira's condensed consolidated financial position, results of operations or cash flows upon adoption of this guidance. See Note 21 for the disclosures resulting from adoption of this guidance.
	In July 2013, the FASB issued ASU 2013-10, “Inclusion of the Fed Funds Effective Swap Rate (or Overnight Index Swap Rate) as a Benchmark Interest Rate for Hedge Accounting Purposes” (“ASU 2013-10”). ASU 2013-10 allows the Federal Funds Effective Swap Rate (also referred to as the Overnight Index Swap rate in the US) to be designated as a benchmark interest rate for hedge accounting purposes. The amendments also remove the restriction on using different benchmark rates for similar hedges. ASU 2013-10 is effective prospectively for qualifying new or redesignated hedging relationships entered into on or after July 17, 2013. There was no impact to Hospira's condensed consolidated financial position, results of operations or cash flows upon adoption of this guidance.
	Significant Accounting Policies
	Supplier Advances
	Hospira has advanced a cumulative $60.0 million to Celltrion, Inc. and Celltrion Healthcare, Inc. (“Celltrion") through September 30, 2013 for the expected purchase of certain biosimilar products. A portion of the advances have been settled with product receipts. Additional supplier advances for these products may be required over the next two years, the timing of which is based on estimated regulatory approval dates and commercial launch dates. Hospira may distribute and market additional products sourced from Celltrion which would require additional advances.
	Hospira has and may continue to make advances to Orchid Chemicals & Pharmaceuticals Ltd. ("Orchid") to supply certain active pharmaceutical ingredient ("API") products, some of which may be settled upon the close of the pending acquisition transaction described in Note 2 or settled upon receipt of API products. The outstanding advances to this supplier were $41.5 million as of September 30, 2013.
	Total supplier advances were $93.9 million and $92.9 million as of September 30, 2013 and December 31, 2012, respectively, and are included in Prepaid expenses and Other assets, in the condensed consolidated balance sheets. Supplier advances are in some cases long-term, refundable under certain conditions, either interest bearing or interest free, primarily unsecured and subject to credit risk.
	Concentration of Risk
	Hospira provides credit to its customers in the normal course of business and does not require collateral. In estimating the allowance for doubtful accounts, management considers historical collections, the past-due status of receivables and economic conditions. Hospira conducts business with certain government-supported customers and distributors, including those in Italy, Spain, Portugal and Greece, where credit and economic conditions continue to present challenges. While the economic conditions in these countries has not significantly impacted Hospira's ability to collect these receivables, such conditions have resulted, and may continue to result, in delays in the collection of receivables. Hospira continually evaluates these receivables, particularly in Italy, Spain, Portugal and Greece and other parts of Europe for potential risks associated with sovereign credit ratings and governmental healthcare funding and reimbursement practices. In addition, Hospira monitors economic conditions and other fiscal developments in these countries. As of September 30, 2013, Hospira's trade receivables in Italy, Spain, Portugal and Greece totaled $114.2 million (gross) and $107.9 million (net of allowances). Of these net trade receivables, $41.7 million and $52.1 million related to customers in Italy and Spain, respectively. As of September 30, 2013, 91.7% of the Italy and 93.6% of the Spain net receivables were from public hospitals primarily funded by the government.

Business_Acquisition

Business Acquisition	9 Months Ended
	Sep. 30, 2013
Business Combinations [Abstract]	'
Business Acquisition	'
	Business Acquisition
	Orchid
	On August 29, 2012, Hospira, through its wholly-owned subsidiary, Hospira Healthcare India Private Limited, ("Hospira India") entered into a definitive agreement (the “Agreement”) with Orchid to acquire from Orchid its penem and penicillin API business for $202.5 million in cash. In March 2013, the Agreement was amended to increase the purchase price to approximately $218 million to include additional assets to be purchased by Hospira that are related to the assets previously subject to the original Agreement and to change the purchase price currency from U.S. dollar to Indian rupee, which may result in a higher or lower payment upon close based upon the currency fluctuations between the Indian rupee and the U.S. dollar. As part of the Agreement, Hospira re-characterized $15.0 million of previous inventory supply advances as an advanced payment of the purchase price to be settled at closing, and is subject to credit risk (see Note 1 for further information regarding advances to Orchid). In addition, supplier advances to Orchid made subsequent to the Agreement and outstanding as of closing will be re-characterized as an advanced payment of the purchase price to be settled at closing. The pending acquisition includes a U.S. Food and Drug Administration ("FDA") approved manufacturing facility located in Aurangabad, India, and a research and development facility based in Chennai, India, along with the related assets and employees associated with those operations. Orchid is a current supplier of APIs to Hospira and will continue to supply cephalosporin APIs following the pending acquisition. During the three and nine months ended September 30, 2013, Hospira incurred $1.2 million and $3.9 million, respectively, of acquisition and integration-related costs, reported in Selling, general and administrative, and expects to incur additional costs in 2013 and 2014. Cumulative acquisition and integration-related costs as of September 30, 2013 were $5.0 million.
	The Agreement contains customary covenants between Hospira India and Orchid. The transaction is subject to customary closing conditions and regulatory approvals and it is possible that the Agreement may be further modified by Hospira India and Orchid prior to closing to reflect additional negotiations and regulatory considerations. The customary closing conditions include Orchid transferring the business and related assets to Hospira with satisfactory release of encumbrances, which may be delayed as Orchid attempts to obtain creditor and other necessary approvals, among other factors. Hospira expects to close the transaction in the first half of 2014, but can give no assurance that the transaction will be consummated during that time period, or at all.

Restructuring_Actions

Restructuring Actions	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Restructuring Actions	'
	Restructuring Actions
	Hospira aims to achieve a culture of continuous improvement that will enhance its efficiency, effectiveness and competitiveness to improve its cost base. Hospira has taken a number of actions to reduce operating costs and optimize operations. The net charges related to these actions consist primarily of severance and other employee benefit costs, impairments, other asset (inventory) charges, other exit costs, contract termination costs and gains or losses on disposal of assets.
	Facilities Optimization
	In June 2012, Hospira initiated plans to exit a specialty injectable drug packaging and inspection finishing operation at one facility and commence modernization of drug finishing operations, including installing additional automated visual inspection equipment, at other existing facilities. As a result, primarily in the Americas segment, Hospira incurred equipment and facility impairment charges of $17.4 million, which are reported in Restructuring and impairment for the nine months ended September 30, 2012. In April 2013, Hospira terminated its lease contract without incurring significant lease termination charges upon final exit from the operation.
	Other Restructuring
	From time to time Hospira incurs costs to implement restructuring actions for specific initiatives. In June 2012, Hospira initiated plans to discontinue a non-strategic product line. As a result, in the Americas segment, Hospira incurred equipment impairment charges of $12.1 million during the nine months ended September 30, 2012, which are reported in Restructuring and impairment. In addition, Hospira incurred other asset (inventory) charges of $4.9 million and $0.9 million of contract termination charges related to the product line discontinuation during the nine months ended September 30, 2012, , both of which are reported in Cost of products sold. Additionally, in August 2012, Hospira sold a non-strategic product line and recognized a $1.9 million gain upon disposition reported in Restructuring and impairment.
	In late 2012 and continuing into 2013, Hospira incurred costs, primarily in the Asia Pacific ("APAC") and Europe, Middle East and Africa ("EMEA") segments, to optimize both commercial organizational structures and exit device products in certain APAC markets. The aggregate costs are reported in Restructuring and impairment and include primarily severance charges of $11.4 million and contract termination charges of $3.1 million. Of the aggregate costs, $3.1 million and $7.6 million were incurred in the three and nine months ended September 30, 2013, respectively, and $6.9 million were incurred in the three months ended December 31, 2012.
	Restructuring Actions Activity
	The following summarizes the aggregate restructuring activity for the nine months ended September 30, 2013:
	(dollars in millions)	Employee-Related			Other			Total
		Benefit Costs
	Balance at January 1, 2013	$	3.5		$	3.6		$	7.1
	Costs incurred	7.6			—			7.6
	Payments	(6.0		)	(1.5		)	(7.5		)
	Balance at September 30, 2013	$	5.1		$	2.1		$	7.2

Device_Strategy

Device Strategy	9 Months Ended
	Sep. 30, 2013
Device Strategy [Abstract]	'
Device Strategy	'
	Device Strategy
	On May 1, 2013, Hospira announced its new Device Strategy, and launched an initiative over the next two to three years that establishes a streamlined and modernized product portfolio to address customer needs and position Hospira for future innovation and growth, while supporting continued advancement of device remediation, including device quality improvement efforts. Actions over the next two to three years include investments in (i) modernizing and streamlining Hospira's installed base of devices through retirement and replacement programs, (ii) strengthening its device quality systems/processes and (iii) developing next generation technology with additional safety features to support further modernization of its installed base. Under the retirement and replacement actions, Hospira will focus on retiring less robust and/or older pump technology from the market and initiating customer replacement programs. Hospira anticipates, among alternatives to be provided to customers, that it will offer customer sale allowances and/or accommodations which may be used as a credit for transition to alternative technology.
	In connection with the Device Strategy, Hospira expects to incur aggregate charges related to these actions in the range of approximately $300 million to $350 million on a pretax basis. The total estimated aggregate charges include pre-tax cash costs of approximately $240 million to $290 million. Major types of cash costs include the following: (i) customer sales allowances; (ii) customer accommodations, contract termination, and pump collection and destruction costs; and (iii) pump retirement and replacement program administration, quality systems/process improvement, consulting costs and other costs. Further, of the total pre-tax charges, approximately $60 million relates to non-cash charges for various asset charges, primarily pump inventory charges, other pump-related asset impairments and accelerated depreciation on production equipment and Hospira-owned pumps in service.
	The charges incurred for the Device Strategy, primarily in the Americas segment, were reported as follows:
		Three Months Ended September 30, 2013		Nine Months Ended September 30, 2013		Line Item in the
						Condensed Consolidated
	(dollars in millions)					Statement of Income (Loss)
	Customer sales allowances	$	—	$	104.3	Net sales
	Consulting, customer accommodations, contract termination, collection and destruction, and other costs	14.8		56.1		Cost of products sold
	Inventory charges	0.9		46.7		Cost of products sold
	Other asset impairments and accelerated depreciation	3.2		10.3		Restructuring and impairment
	Total charges	$	18.9	$	217.4
	See Note 16 for Device Strategy related and other accrual activity for the nine months ended September 30, 2013.

Collaborative_Arrangements

Collaborative Arrangements	9 Months Ended
	Sep. 30, 2013
Collaborative Arrangements [Abstract]	'
Collaborative Arrangements	'
	Collaborative Arrangements
	Hospira enters into collaborative arrangements with third parties for product development and commercialization. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. Hospira’s rights and obligations under these collaborative arrangements vary. These collaborations usually involve various activities including research and development, manufacturing, marketing and sales, and distribution.
	On April 29, 2013, Hospira and NovaQuest Co-Investment Fund I, L.P. (“NovaQuest”) entered into a collaborative arrangement for the following biosimilar products (the “Products”): Hospira's erythropoietin (in the U.S. and Canada), filgrastim (in the U.S.) and pegylated filgrastim (globally). Hospira will be responsible for development, regulatory approval, commercialization and distribution of the Products. NovaQuest will contribute up to $150.0 million of development funding, and such amounts will be recorded as an offset to Research and development expense as incurred. In exchange for the development funding, Hospira will make milestone payments to NovaQuest upon achieving the first commercial sale for each Product, and such payments will be expensed to Cost of products sold as incurred. Hospira will also be required to pay NovaQuest royalties based upon commercial net sales of the Products. In certain instances that result in the delay or failure of the Products to be marketed (other than the failure of the Products to achieve regulatory approval), Hospira may be obligated to make certain payments to NovaQuest as compensation for such unanticipated events. In these circumstances, reimbursement will be made in the form of royalties related to certain sales of Hospira's on-market products. Hospira's total payments to NovaQuest inclusive of the milestones and royalties are capped at a multiple of development funding, which in any reported period could be significant. During the three and nine months ended September 30, 2013, in connection with the NovaQuest agreement, Hospira recognized an offset for development funding of $22.1 million and $36.4 million to Research and development expense, respectively.
	For information on other Hospira collaborative arrangements see Note 4 to Hospira’s consolidated financial statements included in Hospira’s 2012 Form 10-K.

Investments

Investments	9 Months Ended
	Sep. 30, 2013
Investments [Abstract]	'
Investments	'
	Investments
	Investments include equity-method investments in which Hospira has significant influence but not the majority of the equity or risks and rewards. The majority of Hospira’s equity-method investments consist of a 50% ownership interest in a joint venture, Zydus Hospira Oncology Private Limited (“ZHOPL”) with Cadila Healthcare Limited, a pharmaceutical company located in Ahmedabad, India. Equity income from affiliates, net, including the ZHOPL equity investment, was $2.7 million and $6.9 million for the three months ended September 30, 2013 and 2012, respectively. Equity income from affiliates, net, including the ZHOPL equity investment, was $12.7 million and $27.0 million for the nine months ended September 30, 2013 and 2012, respectively. During the nine months ended September 30, 2013, distributions received from ZHOPL were $30.1 million. No distributions were received from ZHOPL during the nine months ended September 30, 2012.
	Combined income statement financial information of unconsolidated equity method investments is as follows:
		Nine Months Ended September 30,
	(dollars in millions)	2013		2012
	Revenue	$	69.9	$	97.7
	Operating expenses	33.3		25.1
	Operating income	36.6		72.6
	Net Income	28.9		59
	During the three and nine months ended September 30, 2013, Hospira recognized non-cash impairment charges of $2.7 million and $11.0 million, respectively, in Other expense, net to impair equity and cost method investments. The impairments were primarily due to a decline in market value of the investments based on management's assessment of future cash flows or earnings from the investments. During the nine months ended September 30, 2012, Hospira recognized and impairment charge of $8.4 million in Other expense, net to impair a cost-method investment, primarily due to the investment's capital call that indicated a decline in the market value.
	During the three and nine months ended September 30, 2013, Hospira assessed the decline in the market value of its marketable equity securities to be other-than-temporary, primarily due to the nature and severity of the investment's decline in market value and the near-term prospects for recovery to the original invested value. Accordingly, Hospira recognized impairment charges of $0.4 million and $3.5 million, respectively, in Other expense, net.

Fair_Value_Measures

Fair Value Measures	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Measures	'
	Fair Value Measures
	The following table summarizes the basis used to measure certain assets and liabilities at fair value in the balance sheets:
				Fair Value Measurements at Reporting Date, Using:
				Quoted Prices		Significant
				in Active Markets for		Other
				Identical Items		Observable
		September 30,				Inputs		Significant
								Unobservable
								Inputs
	(dollars in millions)	2013		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency forward exchange contracts	$	1.2	$	—	$	1.2	$	—
	Available-for-sale marketable equity securities	2.3		2.3		—		—
	Financial Liabilities:
	Foreign currency forward exchange contracts	2.5		—		2.5		—
				Fair Value Measurements at Reporting Date, Using:
				Quoted Prices		Significant
				in Active Markets for		Other
				Identical Items		Observable
		December 31,				Inputs		Significant
								Unobservable
								Inputs
	(dollars in millions)	2012		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency forward exchange contracts	$	0.6	$	—	$	0.6	$	—
	Available-for-sale marketable equity securities	5.9		5.9		—		—
	Financial Liabilities:
	Foreign currency forward exchange contracts	0.9		—		0.9		—
	The fair value of the Level 1 assets is based on quoted market prices of the identical underlying security in an active market. The fair value of cash and cash equivalents, which include money market fund instruments, approximate their carrying value due to their short-term nature, and are within Level 1 of the fair value hierarchy. The fair value of the Level 2 assets and liabilities is primarily based on market observable inputs to quoted market prices, benchmark yields and broker/dealer quotes. Level 3 inputs, as applicable, are unobservable inputs which reflect assumptions developed by management to measure assets and liabilities at fair value.
	The carrying values of certain financial instruments, primarily including accounts receivable, accounts payable and short-term borrowings, approximate their estimated fair values due to their short-term nature. The carrying value and estimated aggregate fair value, based primarily on market prices (Level 1), of the senior unsecured notes are as follows:
		September 30, 2013				December 31, 2012
	(dollars in millions)	Carrying		Fair Value		Carrying		Fair Value
		Value				Value
	Senior unsecured notes	$	1,750.00	$	1,864.70	$	1,700.00	$	1,865.70

Financial_Instruments_and_Deri

Financial Instruments and Derivatives	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Financial Instruments and Derivatives	'
	Financial Instruments and Derivatives
	Hospira’s operations are exposed to market risk primarily due to changes in currency exchange and interest rates. The objective in managing these risks is to reduce volatility on earnings and cash flows. To reduce the risk, Hospira enters into certain derivative financial instruments, when available on a cost-effective basis, to hedge its underlying economic exposure. For a more detailed description of Hospira’s financial instruments and derivatives, see Note 7 to Hospira’s consolidated financial statements included in Hospira’s 2012 Form 10-K.
	The following table summarizes Hospira’s fair value of outstanding derivatives:
		Condensed Consolidated Balance	September 30,			December 31,
	(dollars in millions)	Sheet Presentation	2013			2012
	Derivatives not designated as hedging instruments
	Foreign currency forward exchange contracts:	Other receivables	$	1.2		$	0.6
		Other accrued liabilities	2.5			0.9
	The impact on earnings from derivatives activity was as follows:
		Presentation of Loss (Gain)	Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	Recognized on Derivatives	2013			2012			2013		2012
	Derivatives not designated as hedging instruments
	Foreign currency forward exchange contracts	Other expense, net	$	(3.0	)	$	(5.3	)	$	—	$	1.1
	In November 2013, Hospira entered into foreign currency exchange option contracts to hedge the pending acquisition of Orchid's penem and penicillin API business. See Note 2 for further information regarding the pending acquisition. The foreign currency option contracts, with an aggregate notional value of 7.5 billion Indian rupees, had a net premium payable of $1.6 million at inception. These transactions have been entered into to mitigate a portion of the exposure resulting from movements of the U.S. dollar against the Indian rupee in connection with the future anticipated purchase price. Since these derivatives are hedges of foreign currency risk for a business combination denominated in a foreign currency, the change in the value of the derivatives will be recognized in Other expense, net, in the condensed consolidated financial statements.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Inventories, net	'
	Inventories, Net
	Inventories, net consist of the following:
		September 30,		December 31,
	(dollars in millions)	2013		2012
	Finished products	$	428.6	$	445.6
	Work in process	320.7		262.2
	Materials	322.1		290
	Total	$	1,071.40	$	997.8
	Inventory reserves were $144.5 million and $126.8 million at September 30, 2013 and December 31, 2012, respectively. See Note 4 for further details regarding the increase in inventory reserves.

Property_and_equipment_net

Property and equipment, net	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and equipment, net	'
	Property and Equipment, Net
	Property and equipment, net consists of the following:
		September 30,			December 31,
	(dollars in millions)	2013			2012
	Property and equipment, at cost	$	3,170.00		$	3,067.50
	Accumulated depreciation	(1,683.0		)	(1,622.4		)
	Total property and equipment, net	$	1,487.00		$	1,445.10

Goodwill_and_Intangible_assets

Goodwill and Intangible assets, net	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible assets, net	'
	Goodwill and Intangible Assets, Net
	The following summarizes Goodwill and Intangible assets, net activity:
					Intangible
	(dollars in millions)	Goodwill			assets, net
	Balance at December 31, 2012	$	1,079.10		$	266.8
	Additions	—			14.4
	Amortization	—			(63.8		)
	Impairments	—			(5.2		)
	Currency translation effect and other	(20.5		)	(20.2		)
	Balance at September 30, 2013	$	1,058.60		$	192
	Through the three and nine months ended September 30, 2013, Hospira recognized intangible asset impairment charges of $5.2 million primarily related to product rights on an antibiotic product due to supply constraints and a cardiovascular product due to increased competition and related price erosion. Intangible asset impairment charges are reported in Restructuring and impairment.
	Intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives (1 to 16 years, weighted average 10 years). Indefinite lived intangibles, principally in-process research and development ("IPR&D"), are not amortized until successful completion or regulatory approval. Intangible asset amortization expense was $20.5 million and $20.5 million for the three months ended September 30, 2013 and 2012, respectively. Intangible asset amortization expense was $63.8 million and $62.6 million for the nine months ended September 30, 2013 and 2012, respectively. Intangible asset amortization is estimated at $22.5 million for the remainder of 2013, $76.6 million for 2014, $52.4 million for 2015, $25.7 million for 2016, and $15.7 million for 2017.
	Intangible assets, net consist of the following:
		Gross Carrying Amount						Accumulated Amortization						Intangible assets, net
		September 30,			December 31,			September 30,			December 31,			September 30,		December 31,
	(dollars in millions)	2013			2012			2013			2012			2013		2012
	Product rights and other	$	575.5		$	624.2		$	(413.9	)	$	(389.0	)	$	161.6	$	235.2
	Customer relationships	11.9			12.7			(7.5		)	(6.8		)	4.4		5.9
	IPR&D	2.1			3.8			—			—			2.1		3.8
	Technology	45.3			36.7			(21.4		)	(14.8		)	23.9		21.9
		$	634.8		$	677.4		$	(442.8	)	$	(410.6	)	$	192	$	266.8

Other_Assets

Other Assets	9 Months Ended
	Sep. 30, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Other assets	'
	Other Assets
	Other assets consist of the following:
		September 30,		December 31,
	(dollars in millions)	2013		2012
	Supplier advances	$	57.8	$	72.8
	Net investment in sales-type leases, less current portion	22.3		27.9
	All other	69.3		67.9
	Total	$	149.4	$	168.6
	See Note 1 for further detail regarding supplier advances.

SalesType_Leases

Sales-Type Leases	9 Months Ended
	Sep. 30, 2013
Leases [Abstract]	'
Sales-Type Leases	'
	Sales-Type Leases
	The net investment in sales-type leases of certain medication management products consist of the following:
			September 30,			December 31,
	(dollars in millions)		2013			2012
	Minimum lease payments receivables		$	36.1		$	44.1
	Unearned interest income		(3.6		)	(5.0		)
	Net investment in sales-type leases		32.5			39.1
	Current portion (1)		(10.2		)	(11.2		)
	Net investment in sales-type leases, less current portion (1)		$	22.3		$	27.9
	(1)	The current and long-term portions are reported in Trade receivables and Other assets, respectively.
	Hospira monitors the credit quality of sales-type leases and recognizes an allowance for credit loss based on historical loss experience. As of September 30, 2013 and December 31, 2012, allowance for credit losses and amounts past due 90 days for sales-type leases were not material.

Other_Accrued_Liabilities

Other Accrued Liabilities	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Other Accrued Liabilities	'
	Other Accrued Liabilities
	Other accrued liabilities consist of the following:
		September 30,		December 31,
	(dollars in millions)	2013		2012
	Accrued rebates	$	145.6	$	143.4
	Income taxes payable	9.2		54.3
	Product recall, customer sales allowances, customer accommodations and other related accruals	86.7		56.6
	Accrued returns	20.4		21.7
	All other	256.2		304.3
	Total Other accrued liabilities	$	518.1	$	580.3
	See Note 4 and Note 16 for further details regarding the increase in Product recall, customer sales allowances, customer accommodations and other related accruals. In addition, see Note 19 for further detail regarding the decrease in Income taxes payable.

PostRetirement_Obligations_and

Post-Retirement Obligations and Other Long-term Liabilities	9 Months Ended
	Sep. 30, 2013
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]	'
Post-Retirement Obligations and Other Long-term Liabilities	'
	Post-Retirement Obligations and Other Long-term Liabilities
	Post-retirement obligations and other long-term liabilities consist of the following:
		September 30,		December 31,
	(dollars in millions)	2013		2012
	Accrued post-retirement medical and dental costs	$	49.5	$	51.3
	Pension liabilities	73.5		80.3
	Unrecognized tax benefits, including penalties and interest	49.8		62
	Product recall, customer sales allowances, customer accommodations and other related accruals	128		54.1
	Accrued returns	10		7.1
	All other	45.2		51.7
	Total	$	356	$	306.5
	See Note 4 and Note 16 for further details regarding the increase in Product recall, customer sales allowances, customer accommodations and other related accruals.

Product_Recalls_Customer_Sales

Product Recalls, Customer Sales Allowances, Customer Accomodations and Other Related Accruals	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Product Recalls and Other Related Accruals	'
	Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals
	Accruals for various product recalls, customer sales allowances, customer accommodations, and other related accruals were $214.7 million and $110.7 million as of September 30, 2013 and December 31, 2012, respectively, and the current and long-term portions are reported in Other accrued liabilities and Post-retirement obligations and other long-term liabilities on the condensed consolidated balance sheets. Customer sales allowance charges are recognized in Net sales, while charges associated with product recalls, customer accommodations, and other related costs are recognized in Cost of products sold.
	The following summarizes product recalls, customer sales allowances, customer accommodations, and other related accrual activity (including certain Device Strategy charges of $137.7 million, see Note 4) for the nine months ended September 30, 2013:
	(dollars in millions)
	Balances at January 1, 2013	$	110.7
	Provisions	138.2
	Payments	(34.2		)
	Balances at September 30, 2013	$	214.7
	See Note 4 for further details regarding the increase in the balance in 2013.

Pension_and_PostRetirement_Ben

Pension and Post-Retirement Benefits	9 Months Ended
	Sep. 30, 2013
Compensation and Retirement Disclosure [Abstract]	'
Pension and Post-Retirement Benefits	'
	Pension and Post-Retirement Benefits
	Retirement plans consist of defined benefit and legislated obligations such as employee severance indemnity plans (“pension plans”), post-retirement medical and dental plans (“medical and dental plans”) and defined contribution plans. Plans cover certain employees primarily in the U.S.
	Net periodic benefit cost recognized for the pension plans and medical and dental plans were as follows:
		Pension Plans
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2013			2012			2013			2012
	Service cost for benefits earned during the period	$	0.4		$	0.3		$	1.1		$	1
	Interest cost on projected benefit obligations	5.9			6			17.7			17.9
	Expected return on plans' assets	(7.8		)	(8.1		)	(23.5		)	(24.2		)
	Amortization of net actuarial losses	4.7			4.7			14.3			14.1
	Net periodic benefit cost	$	3.2		$	2.9		$	9.6		$	8.8
		Medical and Dental Plans
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2013			2012			2013			2012
	Service cost for benefits earned during the period	$	0.1		$	—		$	0.2		$	0.1
	Interest cost on projected benefit obligations	0.5			0.6			1.5			1.7
	Amortization of net actuarial losses	0.1			0.2			0.3			0.5
	Net periodic benefit cost	$	0.7		$	0.8		$	2		$	2.3
	Hospira’s funding policy requires contributions to our defined benefit plans equal to the amounts necessary to, at a minimum, satisfy the funding requirements as prescribed by Federal laws and regulations. In addition, Hospira does make discretionary contributions when management deems it is prudent to do so. Based on current Federal laws and regulations, Hospira does not have a requirement to make a cash contribution to its U.S. pension plan in 2013, nor does Hospira expect to make any discretionary cash contributions in 2013.
	Certain Hospira employees in the U.S. and Puerto Rico participate in the Hospira 401(k) Retirement Savings Plan. Hospira’s expenses for this defined contribution plan for the three months ended September 30, 2013 and 2012 were $11.0 million and $9.9 million, respectively. For the nine months ended September 30, 2013 and 2012, expenses were $32.1 million and $27.9 million, respectively.

Shortterm_Borrowings_and_Longt

Short-term Borrowings and Long-term Debt	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Short-term Borrowings and Long-term Debt	'
	Short-term Borrowings and Long-term Debt
	In August 2013, Hospira issued, in a registered public offering, $350.0 million principal amount of 5.20% notes due on August 12, 2020 and $350.0 million principal amount of 5.80% notes due on August 12, 2023 ("2020 and 2023 Notes"). In September 2013, the net proceeds of the 2020 and 2023 Notes, after deducting approximately $2.1 million of bond discounts and underwriting fees of $6.1 million plus cash on-hand, were used to extinguish $400.0 million principal amount of 5.90% notes originally due June 2014, $250.0 million principal amount of 6.40% notes originally due May 2015 ("2014 and 2015 Notes"), accrued interest and a make-whole premium payment of $39.8 million. In aggregate, Hospira incurred $33.4 million in charges associated with the early extinguishment of the 2014 and 2015 Notes, which is reported in Other expenses, net, in the three and nine months ended September 30, 2013. The early debt extinguishment charges include a make-whole premium, write-off of previously capitalized debt issuance costs, discounts and deferred gains on interest rate hedges.
	In August 2013, Hospira terminated the forward starting interest rate swaps, notional amount of $550 million, which had effectively fixed the benchmark interest rates upon entering into the transactions in July 2013 and up to the issuance of the 2020 and 2023 Notes. As a result of the swap terminations, Hospira paid $3.6 million, including interest. The corresponding loss will be deferred in Accumulated other comprehensive loss and amortized into Interest expense over the terms of the 2020 and 2023 notes, respectively.
	As of September 30, 2013, Hospira had a $1.0 billion unsecured revolving credit facility (“Revolver”) maturing in October 2016. For the nine months ended and as of September 30, 2013, Hospira had no amounts borrowed or otherwise outstanding under the Revolver. Amounts borrowed under the Revolver, if any, are included in the leverage ratio covenant discussed below and may limit Hospira's availability for borrowings to less than $1.0 billion. As of September 30, 2013, Hospira had approximately $541 million of availability for borrowings under the Revolver.
	The Revolver and the indenture governing Hospira's senior notes contain, among other provisions, covenants with which Hospira must comply while they are in force. The Revolver has a financial covenant that requires Hospira to maintain a maximum leverage ratio (consolidated total debt to consolidated net earnings before financing expense, taxes and depreciation, amortization, adjusted for certain non-cash items and agreed-upon charges).
	On April 30, 2013, Hospira entered into an amendment to the Revolver that, among other things, permits Hospira to add back certain charges related to the items identified under the sections captioned “Certain Quality and Product Related Matters” and “Device Strategy” in Item 2 when calculating the leverage ratio. In addition, the maximum leverage ratio was increased from 3.50 to 1.00 to 3.75 to 1.00 for the periods ended March 31, 2013 through December 31, 2014, reverting to 3.50 to 1.00 thereafter. In connection with the Revolver amendment, Hospira incurred various fees and expenses of approximately $0.5 million. Such fees and expenses will be amortized to Interest expense over the remaining term of the Revolver.
	Hospira was in compliance with the maximum leverage ratio, and with all other covenants in the Revolver and indenture governing Hospira's senior notes, for the period ended September 30, 2013.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	Taxes on income reflect the estimated annual effective rates, excluding the effect of significant unusual items. The effective tax rates are less than the statutory U.S. federal income tax rate principally due to the benefit of tax exemptions, of varying durations, in certain non-U.S. taxing jurisdictions.
	Hospira remains subject to tax examinations, which are in various stages, in the following major tax-paying jurisdictions: for years 2006 forward for Italy, for years 2007 forward for Australia, for years 2009 forward for Canada and for years 2010 forward for the United Kingdom and the United States. Hospira estimates that within the next twelve months a decrease of up to $10 million in the balance of unrecognized tax benefits could occur as a result of audit settlements or statute expirations.
	In July 2013, a payment of $53.1 million was made to finalize the 2008 and 2009 U.S. federal tax audit which was effectively settled in 2012.

Shareholders_Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2013
Stockholders' Equity Note [Abstract]	'
Shareholders' Equity	'
	Shareholders’ Equity
	Common Stock
	Hospira is authorized to issue 400.0 million shares of common stock, par value $0.01 per share, and 50.0 million shares of preferred stock, par value $0.01 per share. As of September 30, 2013 and December 31, 2012, 179.0 million and 178.4 million common shares were issued and 165.9 million and 165.3 million common shares were outstanding, respectively.
	Treasury Stock
	In April 2011, Hospira’s Board of Directors authorized the repurchase of up to $1.0 billion of Hospira’s common stock. Hospira may periodically repurchase additional shares under this authorization, which will depend on various factors such as cash generation from operations, cash expenditure required for other purposes, current stock price, and other factors. No repurchases were made during the nine months ended September 30, 2013.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive (Loss), net of tax	9 Months Ended
	Sep. 30, 2013
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]	'
Accumulated Other Comprehensive Loss, net of tax	'
	Accumulated Other Comprehensive Loss, Net of Tax
	Changes in Accumulated other comprehensive loss, net of taxes, consists of the following:
	(dollars in millions)		Cumulative Foreign Currency Translation Adjustments(1)			Cumulative Retirement Plans Unrealized Losses(2)			Cumulative Unrealized Gains on Marketable Equity Securities(1)			Cumulative Gains (Losses) on			Total Accumulated Other Comprehensive Loss
												Terminated Cash Flow Hedges(3)
	Balance at January 1, 2013		$	48.1		$	(132.4	)	$	0.4		$	0.7		$	(83.2	)
	Other comprehensive loss before reclassifications		(139.3		)	—			(3.5		)	(2.2		)	(145.0		)
	Amounts reclassified from accumulated other comprehensive loss		—			9			3.5			(0.2		)	12.3
	Balance at September 30, 2013		$	(91.2	)	$	(123.4	)	$	0.4		$	(1.7	)	$	(215.9	)
	(1)	Net of taxes of $0.0 million as of September 30, 2013 and December 31, 2012.
	(2)	Net of taxes of $73.0 million and $78.6 million as of September 30, 2013 and December 31, 2012, respectively.
	(3)	Net of taxes of $(1.0) million and $(0.4) million as of September 30, 2013 and December 31, 2012, respectively.
	The following summarizes reclassifications out of Accumulated other comprehensive loss:
			Amount Reclassified from
			Accumulated Other Comprehensive Loss
	(dollars in millions)		Three Months Ended September 30, 2013			Nine Months Ended September 30, 2013			Line Item in the
									Condensed Consolidated
									Statement of Income (Loss)
	Impairment on marketable equity securities		$	0.4		$	3.5		Other expense, net
			—			—			Income tax benefit
	Net of income taxes		0.4			3.5
	Amortization of gain on terminated cash flow hedges		(0.1		)	(0.2		)	Other expense, net
			—			—			Income tax benefit
	Net of income taxes		(0.1		)	(0.2		)
	Amortization of pension plans actuarial losses		4.7			14.3			(1)
	Amortization of medical and dental plans actuarial losses		0.1			0.3			(1)
	Total before income taxes		4.8			14.6
			(1.9		)	(5.6		)	Income tax benefit
	Net of income taxes		2.9			9
	Total reclassifications for the period		$	3.2		$	12.3
	(1)	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_per_Share

Earnings per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings (Loss) per Share	'
	Earnings (Loss) per Share
	Basic earnings (loss) per share are computed by dividing net income (loss) by the number of weighted average common shares outstanding during the reporting period. Diluted earnings (loss) per share are calculated to give effect to all potentially dilutive common shares that were outstanding during the reporting period, only in the periods in which such effect is dilutive. The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating diluted earnings (loss) per share for the three and nine months ended September 30:
		Three Months Ended September 30,		Nine Months Ended September 30,
	(shares in millions)	2013	2012	2013	2012
	Weighted average basic common shares outstanding	165.7	165.1	165.5	165
	Incremental shares outstanding related to stock-based awards	1.3	0.8	—	1
	Weighted average dilutive common shares outstanding	167	165.9	165.5	166
	For the nine months ended September 30, 2013, 1.0 million incremental shares related to stock-based awards were not included in the computation of diluted earnings (loss) per share because of the net loss during the nine months ended September 30, 2013. The number of outstanding options and awards to purchase Hospira stock for which the exercise price of the options exceeded the average stock price was 8.2 million and 8.5 million for the three and nine months ended September 30, 2013, respectively, and 9.8 million and 9.4 million for the three and nine months ended September 30, 2012, respectively. Accordingly, these options are excluded from the diluted earnings (loss) per share calculation for these periods.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	Stock-Based Compensation
	Hospira’s 2004 Long-Term Stock Incentive Plan, as amended, provides for the grant of shares of stock options, stock appreciation rights, stock awards (restricted stock, restricted stock units, performance shares and performance units), and cash-based awards to employees and non-employee directors. Stock-based compensation expense of $10.4 million and $9.8 million was recognized for the three months ended September 30, 2013 and 2012, respectively. The related income tax benefit recognized was $3.8 million and $3.6 million for the three months ended September 30, 2013 and 2012, respectively. Stock-based compensation expense of $31.1 million and $29.9 million was recognized for the nine months ended September 30, 2013 and 2012, respectively. The related income tax benefit recognized was $11.4 million and $10.4 million for the nine months ended September 30, 2013, and 2012, respectively. As of September 30, 2013, there was $80.7 million of total unrecognized compensation costs related to non-vested share-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 2.6 years.
	Stock Options
	During the nine months ended September 30, 2013, 1.8 million options were granted to certain employees primarily as part of the first quarter 2013 annual stock option grant. These options were awarded at the fair market value at the time of grant, generally vest over four years, and have a seven-year term. The expected life assumption of the options was based on the expected amount of time that options granted are expected to be outstanding, based on historical and forecasted exercise behavior of employees’ post-vesting forfeitures and exercises.
	The weighted average grant date fair value using the Black-Scholes option-pricing model, and the corresponding weighted average assumptions for stock option grants for the three and nine months ended September 30, were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Volatility	31.5		%	31.3		%	30.3		%	31.3		%
	Expected life (years)	5.1			4.8			5.1			4.8
	Risk-free interest rate	1.3		%	0.7		%	0.9		%	0.8		%
	Dividend yield	0		%	0		%	0		%	0		%
	Fair value per stock option	$	11.77		$	9.15		$	8.48		$	10.01
	Performance Share Awards
	During the nine months ended September 30, 2013, 0.2 million performance share awards were granted to key members of management primarily as part of the first quarter 2013 annual grant. These awards vest at the end of the three-year performance cycle. The amount of awards earned is based on a formula measuring performance using relative total shareholder return over interim annual periods and the three-year performance cycle compared to an industry peer group. Based on the actual performance at the end of each interim annual period and the three year performance cycle period, the number of performance share awards earned, which can range between 0% and 200% of the target awards granted, will be satisfied with Hospira common stock.
	The weighted average grant date fair value using the Monte Carlo simulation model and the corresponding weighted average assumptions for the annual performance share award grants, were as follows:
		2013			2012
	Volatility	30.8		%	27.3		%
	Risk-free interest rate	0.4		%	0.4		%
	Dividend yield	0		%	0		%
	Fair value per performance share	$	29.46		$	51.39
	Performance-Based Restricted Stock Units
	During the nine months ended September 30, 2013, 0.2 million performance-based restricted stock units were granted to key members of management primarily as part of the first quarter 2013 annual grant. These awards vest after three years if, during the three year period, Hospira's stock price appreciates to a level of 120% of the fair market value on the grant date, and maintains that level of appreciation for a 30 consecutive day period which was achieved in June 2013.
	The weighted average grant date fair value using the Monte Carlo simulation model and the corresponding weighted average assumptions for the annual performance-based restricted stock units grants, were as follows:
		2013
	Volatility	30.2		%
	Risk-free interest rate	0.4		%
	Dividend yield	0		%
	Fair value per performance share	$	20.81
	Restricted Stock and Units
	During the nine months ended September 30, 2013, 1.1 million restricted stock and units ("restricted awards") were granted to certain employees and the non-employee directors primarily as part of the first quarter 2013 annual grant. Hospira issues restricted awards with a vesting period ranging from one to three years. The weighted average grant date fair value of restricted awards granted was $29.00 per restricted award.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Loss Contingency, Information about Litigation Matters [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Hospira is involved in various claims and legal proceedings, as well as product liability claims, regulatory matters and proceedings related to Hospira’s business, including in some instances when Hospira operated as part of Abbott Laboratories.
	Hospira is involved in two patent lawsuits concerning Hospira’s PrecedexTM (dexmedetomidine hydrochloride), a proprietary sedation agent. On September 4, 2009, Hospira brought suit against Sandoz International GmbH and Sandoz, Inc. for patent infringement. The lawsuit, which alleges infringement of U.S. Patents 4,910,214 (“214”) (expires January 15, 2014) and 6,716,867 (“867”) (expires October 1, 2019), is pending in the U.S. District Court for the District of New Jersey: Hospira, Inc. and Orion Corp. v. Sandoz International GmbH and Sandoz, Inc. (D. N.J. 2009). The lawsuit is based on Sandoz’s “Paragraph IV” notice indicating that Sandoz has filed an abbreviated new drug application (“ANDA”) with the FDA for a generic version of PrecedexTM. Hospira is seeking a judgment of infringement, injunctive relief and costs. Sandoz’s ANDA has received tentative approval from the FDA. Trial of this matter has concluded. On April 30, 2012, the court issued its opinion. The court ruled that: (i) the 214 patent is valid and infringed by the Sandoz defendants; and (ii) the 867 patent is invalid. Hospira and Sandoz have both appealed the District Court ruling to the United States Court of Appeals for the Federal Circuit. On November 12, 2010, Hospira brought suit against Caraco Pharmaceutical Laboratories, Ltd. for patent infringement. The lawsuit, which alleges infringement of U.S. Patent No. 6,716,867 (referred to above) is pending in the U.S. District Court for the Eastern District of Michigan: Hospira, Inc. and Orion Corporation v. Caraco Pharmaceutical Laboratories, Ltd., No. 10-cv-14514 (E.D. Mich. 2010). The lawsuit is based on Caraco’s “Paragraph IV” notice indicating that Caraco has filed an ANDA with the FDA for a generic version of PrecedexTM. Hospira is seeking a judgment of infringement, injunctive relief and costs. Caraco’s ANDA has received tentative approval from the FDA.
	Hospira and certain of its corporate officers and former corporate officers are defendants in a lawsuit alleging violations of the Securities and Exchange Act of 1934: City of Sterling Heights General Employees’ Retirement System, Individually and on behalf of all others similarly situated vs. Hospira, Inc., F. Michael Ball, Thomas E. Werner, James H. Hardy, Jr., and Christopher B. Begley, second amended complaint filed March 15, 2013 and pending in the United States District Court for the Northern District of Illinois. James Hardy has been dismissed as a defendant in the lawsuit. The lawsuit alleges, generally, that the defendants issued materially false and misleading statements regarding Hospira’s financials and business prospects and failed to disclose material facts affecting Hospira’s financial condition. The lawsuit alleges a class period from February 4, 2010 (announcement of Q4, 2009 financial results) through October 17, 2011 (Hospira announced preliminary financial results for Q3, 2011 on October 18, 2011). The lawsuit seeks class action status and damages including interest, attorneys’ fees and costs.
	Hospira has been named as a nominal defendant in two shareholder derivative lawsuits (one dismissed) which name as defendants certain Hospira officers, certain former officers and members of Hospira’s Board of Directors. The cases are: Lori Ravenscroft Geare and Robert J. Casey, II, Derivatively for the Benefit of Hospira, Inc. v. Christopher B. Begley, F. Michael Ball, Thomas E. Werner, Sumant Ramachandra, Irving W. Bailey, II, Jacque J. Sokolov, Barbara L. Bowles, Roger W. Hale, John C. Staley, Connie R. Curran, Heino von Prondzynski, Mark F. Wheeler, Terrence C. Kearney, Ronald A. Matricaria and Brian J. Smith and Hospira, Inc. (Nominal Defendant) amended complaint filed in September of 2012 in the United States District Court for the Northern District of Illinois; and Cheryl E. Currie v. Christopher B. Begley, Irving W. Bailey, II, Roger W. Hale, F. Michael Ball, Barbara L. Bowles, Connie R. Curran, Heino von Prondzynski, William G. Dempsey, Jacque J. Sokolov, M.D., John C. Staley, Mark F. Wheeler, M.D., Thomas E. Werner, Terrence C. Kearney, Ronald Squarer and Sumant Ramachandra, M.D. and Hospira, Inc. (Nominal Defendant) ("Currie"), filed in December, 2011 and pending in the Circuit Court of Cook County, Illinois. In general terms, these lawsuits allege breaches of fiduciary duties by the individual defendants and seek damages, purportedly on behalf of Hospira. On October 15, 2012, the court granted defendants' motion to dismiss the Currie case in its entirety.
	In April 2012, the Hospira Board of Directors received a letter from a law firm on behalf of a Hospira shareholder regarding “Demand Upon the Board of Directors to Investigate Claims, Initiate Legal Action and Take Necessary and Appropriate Remedial Measures.” The letter requests investigation of matters entirely covered by the securities and derivative lawsuits that were previously filed, as set forth above. Hospira received a second letter in May 2013 requesting an inspection of Hospira's books and records pursuant to Delaware law. The letter references the securities litigation described above. Hospira has responded to the inspection request.
	Hospira is subject to oversight of its business by regulatory agencies, which may lead to inspection observations (commonly referred to as Form 483 observations in the U.S.), warning letters, voluntary or involuntary product recalls, consent decrees, injunctions to halt manufacturing and distribution of products, import and export bans or restrictions, monetary sanctions, delays in product approvals and other restrictions on operations.
	Hospira’s litigation exposure, including product liability claims, is evaluated each reporting period. Hospira’s accruals, which are not significant at September 30, 2013 and December 31, 2012, are the best estimate of loss. Based upon information that is currently available, management believes that the likelihood of a material loss in excess of recorded amounts is remote.
	Additional legal proceedings may occur that may result in a change in the estimated accruals recorded by Hospira. It is not feasible to predict the outcome of such proceedings with certainty and there can be no assurance that their ultimate disposition will not have a material adverse effect on Hospira’s financial position, cash flows, or results of operations.

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]	'
Segment Information	'
	Segment Information
	Hospira conducts operations worldwide and is managed in three reportable segments: Americas, EMEA and APAC. The Americas segment includes the U.S., Canada and Latin America; the EMEA segment includes Europe, the Middle East and Africa; and the APAC segment includes Asia, Japan, Australia and New Zealand. In 2013, to better reflect how the business is managed, Hospira increased its operating segments to six: (i) U.S., (ii) Canada, (iii) Latin America, (iv) EMEA, (v) Asia and Japan, and (vi) Australia and New Zealand. Hospira has aggregated the U.S., Canada, and Latin America operating segments within the Americas reportable segment. Hospira has also aggregated the Asia and Japan and Australia and New Zealand operating segments within the APAC reportable segment. In all reportable segments, Hospira sells a broad line of products, including specialty injectable pharmaceuticals, medication management, and other pharmaceuticals. Specialty Injectable Pharmaceuticals include generic injectables, proprietary specialty injectables and, in certain markets, biosimilars. Medication Management includes infusion pumps, related software and services, dedicated administration sets, gravity administration sets, and other device products. Other Pharmaceuticals include large volume intravenous solutions, nutritionals and contract manufacturing.
	Hospira’s underlying accounting records are maintained on a legal-entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. For internal management reporting, intersegment transfers of inventory are recorded at standard cost and are not a measure of segment income from operations. The costs of certain corporate functions, stock-based compensation, Interest expense, and Other expense, net that benefit the entire organization are not allocated. The following segment information has been prepared in accordance with the internal accounting policies of Hospira, as described above.
	Reportable segment information:
	The table below presents information about Hospira’s reportable segments for the three months ended September 30:
		Net Sales				Income (Loss) from Operations
	(dollars in millions)	2013		2012		2013			2012
	Americas	$	804.2	$	789.1	$	75.7		$	34.3
	EMEA	123.5		122.9		(14.5		)	(28.0		)
	APAC	80.5		82		(1.5		)	6.9
	Total reportable segments	$	1,008.20	$	994	59.7			13.2
	Corporate functions					(19.5		)	(19.9		)
	Stock-based compensation					(10.4		)	(9.8		)
	Income (Loss) from operations					29.8			(16.5		)
	Interest expense and other expense, net					(62.3		)	(23.9		)
	Loss before income taxes					$	(32.5	)	$	(40.4	)
	The table below presents information about Hospira's reportable segments for the nine months ended September 30:
		Net Sales				(Loss) Income from Operations
	(dollars in millions)	2013		2012		2013			2012
	Americas	$	2,318.90	$	2,369.70	$	147.5		$	150.7
	EMEA	369.9		386.1		(73.5		)	(42.9		)
	APAC	229.6		237.4		(16.7		)	7.7
	Total reportable segments	$	2,918.40	$	2,993.20	57.3			115.5
	Corporate functions					(62.8		)	(57.6		)
	Stock-based compensation					(31.1		)	(29.9		)
	(Loss) Income from operations					(36.6		)	28
	Interest expense and other expense, net					(114.1		)	(77.1		)
	Loss before income taxes					$	(150.7	)	$	(49.1	)
	Net sales and Income (Loss) from operations for the nine months ended September 30, 2013 includes charges of $104.3 million, including $88.4 million in the Americas segment, $13.2 million in the EMEA segment and $2.7 million in the APAC segment related to the Device Strategy. See Note 4 for further information.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Basis of Presentation and Significant Accounting Policies [Abstract]	'
Supplier Advances	'
	Supplier Advances
	Hospira has advanced a cumulative $60.0 million to Celltrion, Inc. and Celltrion Healthcare, Inc. (“Celltrion") through September 30, 2013 for the expected purchase of certain biosimilar products. A portion of the advances have been settled with product receipts. Additional supplier advances for these products may be required over the next two years, the timing of which is based on estimated regulatory approval dates and commercial launch dates. Hospira may distribute and market additional products sourced from Celltrion which would require additional advances.
	Hospira has and may continue to make advances to Orchid Chemicals & Pharmaceuticals Ltd. ("Orchid") to supply certain active pharmaceutical ingredient ("API") products, some of which may be settled upon the close of the pending acquisition transaction described in Note 2 or settled upon receipt of API products. The outstanding advances to this supplier were $41.5 million as of September 30, 2013.
	Total supplier advances were $93.9 million and $92.9 million as of September 30, 2013 and December 31, 2012, respectively, and are included in Prepaid expenses and Other assets, in the condensed consolidated balance sheets. Supplier advances are in some cases long-term, refundable under certain conditions, either interest bearing or interest free, primarily unsecured and subject to credit risk.
Concentration of Risk	'
	Concentration of Risk
	Hospira provides credit to its customers in the normal course of business and does not require collateral. In estimating the allowance for doubtful accounts, management considers historical collections, the past-due status of receivables and economic conditions. Hospira conducts business with certain government-supported customers and distributors, including those in Italy, Spain, Portugal and Greece, where credit and economic conditions continue to present challenges. While the economic conditions in these countries has not significantly impacted Hospira's ability to collect these receivables, such conditions have resulted, and may continue to result, in delays in the collection of receivables. Hospira continually evaluates these receivables, particularly in Italy, Spain, Portugal and Greece and other parts of Europe for potential risks associated with sovereign credit ratings and governmental healthcare funding and reimbursement practices. In addition, Hospira monitors economic conditions and other fiscal developments in these countries.

Restructuring_Actions_Tables

Restructuring Actions (Tables)	9 Months Ended
	Sep. 30, 2013
Restructuring and Related Activities [Abstract]	'
Aggregate restructuring activity	'
	The following summarizes the aggregate restructuring activity for the nine months ended September 30, 2013:
	(dollars in millions)	Employee-Related			Other			Total
		Benefit Costs
	Balance at January 1, 2013	$	3.5		$	3.6		$	7.1
	Costs incurred	7.6			—			7.6
	Payments	(6.0		)	(1.5		)	(7.5		)
	Balance at September 30, 2013	$	5.1		$	2.1		$	7.2

Device_Strategy_Tables

Device Strategy (Tables)	9 Months Ended
	Sep. 30, 2013
Device Strategy [Abstract]	'
Schedule of Device Strategy and Related Costs	'
	The charges incurred for the Device Strategy, primarily in the Americas segment, were reported as follows:
		Three Months Ended September 30, 2013		Nine Months Ended September 30, 2013		Line Item in the
						Condensed Consolidated
	(dollars in millions)					Statement of Income (Loss)
	Customer sales allowances	$	—	$	104.3	Net sales
	Consulting, customer accommodations, contract termination, collection and destruction, and other costs	14.8		56.1		Cost of products sold
	Inventory charges	0.9		46.7		Cost of products sold
	Other asset impairments and accelerated depreciation	3.2		10.3		Restructuring and impairment
	Total charges	$	18.9	$	217.4

Investments_Tables

Investments (Tables)	9 Months Ended
	Sep. 30, 2013
Investments [Abstract]	'
Schedule of combined income statement financial information of unconsolidated equity method investments	'
	Combined income statement financial information of unconsolidated equity method investments is as follows:
		Nine Months Ended September 30,
	(dollars in millions)	2013		2012
	Revenue	$	69.9	$	97.7
	Operating expenses	33.3		25.1
	Operating income	36.6		72.6
	Net Income	28.9		59

Fair_Value_Measures_Tables

Fair Value Measures (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'
Basis used to measure certain assets and liabilities at fair value	'
	The following table summarizes the basis used to measure certain assets and liabilities at fair value in the balance sheets:
				Fair Value Measurements at Reporting Date, Using:
				Quoted Prices		Significant
				in Active Markets for		Other
				Identical Items		Observable
		September 30,				Inputs		Significant
								Unobservable
								Inputs
	(dollars in millions)	2013		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency forward exchange contracts	$	1.2	$	—	$	1.2	$	—
	Available-for-sale marketable equity securities	2.3		2.3		—		—
	Financial Liabilities:
	Foreign currency forward exchange contracts	2.5		—		2.5		—
				Fair Value Measurements at Reporting Date, Using:
				Quoted Prices		Significant
				in Active Markets for		Other
				Identical Items		Observable
		December 31,				Inputs		Significant
								Unobservable
								Inputs
	(dollars in millions)	2012		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency forward exchange contracts	$	0.6	$	—	$	0.6	$	—
	Available-for-sale marketable equity securities	5.9		5.9		—		—
	Financial Liabilities:
	Foreign currency forward exchange contracts	0.9		—		0.9		—
Carrying value and fair value of the senior unsecured notes	'
	The carrying value and estimated aggregate fair value, based primarily on market prices (Level 1), of the senior unsecured notes are as follows:
		September 30, 2013				December 31, 2012
	(dollars in millions)	Carrying		Fair Value		Carrying		Fair Value
		Value				Value
	Senior unsecured notes	$	1,750.00	$	1,864.70	$	1,700.00	$	1,865.70

Financial_Instruments_and_Deri1

Financial Instruments and Derivatives (Tables)	9 Months Ended
	Sep. 30, 2013
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Fair value of outstanding derivatives	'
	The following table summarizes Hospira’s fair value of outstanding derivatives:
		Condensed Consolidated Balance	September 30,			December 31,
	(dollars in millions)	Sheet Presentation	2013			2012
	Derivatives not designated as hedging instruments
	Foreign currency forward exchange contracts:	Other receivables	$	1.2		$	0.6
		Other accrued liabilities	2.5			0.9
Impact on earnings from derivatives activity	'
	The impact on earnings from derivatives activity was as follows:
		Presentation of Loss (Gain)	Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	Recognized on Derivatives	2013			2012			2013		2012
	Derivatives not designated as hedging instruments
	Foreign currency forward exchange contracts	Other expense, net	$	(3.0	)	$	(5.3	)	$	—	$	1.1

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventories	'
	Inventories, net consist of the following:
		September 30,		December 31,
	(dollars in millions)	2013		2012
	Finished products	$	428.6	$	445.6
	Work in process	320.7		262.2
	Materials	322.1		290
	Total	$	1,071.40	$	997.8

Property_and_equipment_net_Tab

Property and equipment, net (Tables)	9 Months Ended
	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'
Property and equipment, net	'
	Property and equipment, net consists of the following:
		September 30,			December 31,
	(dollars in millions)	2013			2012
	Property and equipment, at cost	$	3,170.00		$	3,067.50
	Accumulated depreciation	(1,683.0		)	(1,622.4		)
	Total property and equipment, net	$	1,487.00		$	1,445.10

Goodwill_and_Intangible_assets1

Goodwill and Intangible assets, net (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Summary of Goodwill and Intangible Assets, Net	'
	The following summarizes Goodwill and Intangible assets, net activity:
					Intangible
	(dollars in millions)	Goodwill			assets, net
	Balance at December 31, 2012	$	1,079.10		$	266.8
	Additions	—			14.4
	Amortization	—			(63.8		)
	Impairments	—			(5.2		)
	Currency translation effect and other	(20.5		)	(20.2		)
	Balance at September 30, 2013	$	1,058.60		$	192
Schedule of intangible assets, net	'
	Intangible assets, net consist of the following:
		Gross Carrying Amount						Accumulated Amortization						Intangible assets, net
		September 30,			December 31,			September 30,			December 31,			September 30,		December 31,
	(dollars in millions)	2013			2012			2013			2012			2013		2012
	Product rights and other	$	575.5		$	624.2		$	(413.9	)	$	(389.0	)	$	161.6	$	235.2
	Customer relationships	11.9			12.7			(7.5		)	(6.8		)	4.4		5.9
	IPR&D	2.1			3.8			—			—			2.1		3.8
	Technology	45.3			36.7			(21.4		)	(14.8		)	23.9		21.9
		$	634.8		$	677.4		$	(442.8	)	$	(410.6	)	$	192	$	266.8

Other_Assets_Tables

Other Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'
Schedule of Other assets	'
	Other assets consist of the following:
		September 30,		December 31,
	(dollars in millions)	2013		2012
	Supplier advances	$	57.8	$	72.8
	Net investment in sales-type leases, less current portion	22.3		27.9
	All other	69.3		67.9
	Total	$	149.4	$	168.6

SalesType_Leases_Tables

Sales-Type Leases (Tables)	9 Months Ended
	Sep. 30, 2013
Leases [Abstract]	'
Net investment in sales-type leases	'
	The net investment in sales-type leases of certain medication management products consist of the following:
			September 30,			December 31,
	(dollars in millions)		2013			2012
	Minimum lease payments receivables		$	36.1		$	44.1
	Unearned interest income		(3.6		)	(5.0		)
	Net investment in sales-type leases		32.5			39.1
	Current portion (1)		(10.2		)	(11.2		)
	Net investment in sales-type leases, less current portion (1)		$	22.3		$	27.9
	(1)	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Other Accrued Liabilities	'
	Other accrued liabilities consist of the following:
		September 30,		December 31,
	(dollars in millions)	2013		2012
	Accrued rebates	$	145.6	$	143.4
	Income taxes payable	9.2		54.3
	Product recall, customer sales allowances, customer accommodations and other related accruals	86.7		56.6
	Accrued returns	20.4		21.7
	All other	256.2		304.3
	Total Other accrued liabilities	$	518.1	$	580.3

PostRetirement_Obligations_and1

Post-Retirement Obligations and Other Long-term Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]	'
Components of Post-Retirement Obligations and Other Long-Term Liabilities	'
	Post-retirement obligations and other long-term liabilities consist of the following:
		September 30,		December 31,
	(dollars in millions)	2013		2012
	Accrued post-retirement medical and dental costs	$	49.5	$	51.3
	Pension liabilities	73.5		80.3
	Unrecognized tax benefits, including penalties and interest	49.8		62
	Product recall, customer sales allowances, customer accommodations and other related accruals	128		54.1
	Accrued returns	10		7.1
	All other	45.2		51.7
	Total	$	356	$	306.5

Product_Recalls_Customer_Sales1

Product Recalls, Customer Sales Allowances, Customer Accomodations and Other Related Accruals (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Summary of product recalls and other related accrual activity	'
	The following summarizes product recalls, customer sales allowances, customer accommodations, and other related accrual activity (including certain Device Strategy charges of $137.7 million, see Note 4) for the nine months ended September 30, 2013:
	(dollars in millions)
	Balances at January 1, 2013	$	110.7
	Provisions	138.2
	Payments	(34.2		)
	Balances at September 30, 2013	$	214.7

Pension_and_PostRetirement_Ben1

Pension and Post-Retirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2013
Compensation and Retirement Disclosure [Abstract]	'
Net cost recognized	'
	Net periodic benefit cost recognized for the pension plans and medical and dental plans were as follows:
		Pension Plans
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2013			2012			2013			2012
	Service cost for benefits earned during the period	$	0.4		$	0.3		$	1.1		$	1
	Interest cost on projected benefit obligations	5.9			6			17.7			17.9
	Expected return on plans' assets	(7.8		)	(8.1		)	(23.5		)	(24.2		)
	Amortization of net actuarial losses	4.7			4.7			14.3			14.1
	Net periodic benefit cost	$	3.2		$	2.9		$	9.6		$	8.8
		Medical and Dental Plans
		Three Months Ended September 30,						Nine Months Ended September 30,
	(dollars in millions)	2013			2012			2013			2012
	Service cost for benefits earned during the period	$	0.1		$	—		$	0.2		$	0.1
	Interest cost on projected benefit obligations	0.5			0.6			1.5			1.7
	Amortization of net actuarial losses	0.1			0.2			0.3			0.5
	Net periodic benefit cost	$	0.7		$	0.8		$	2		$	2.3

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive (Loss) Income, net of tax (Tables)	9 Months Ended
	Sep. 30, 2013
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]	'
Accumulated other comprehensive (loss) income, net of taxes	'
	Changes in Accumulated other comprehensive loss, net of taxes, consists of the following:
	(dollars in millions)		Cumulative Foreign Currency Translation Adjustments(1)			Cumulative Retirement Plans Unrealized Losses(2)			Cumulative Unrealized Gains on Marketable Equity Securities(1)			Cumulative Gains (Losses) on			Total Accumulated Other Comprehensive Loss
												Terminated Cash Flow Hedges(3)
	Balance at January 1, 2013		$	48.1		$	(132.4	)	$	0.4		$	0.7		$	(83.2	)
	Other comprehensive loss before reclassifications		(139.3		)	—			(3.5		)	(2.2		)	(145.0		)
	Amounts reclassified from accumulated other comprehensive loss		—			9			3.5			(0.2		)	12.3
	Balance at September 30, 2013		$	(91.2	)	$	(123.4	)	$	0.4		$	(1.7	)	$	(215.9	)
	(1)	Net of taxes of $0.0 million as of September 30, 2013 and December 31, 2012.
	(2)	Net of taxes of $73.0 million and $78.6 million as of September 30, 2013 and December 31, 2012, respectively.
	(3)	Net of taxes of $(1.0) million and $(0.4) million as of September 30, 2013 and December 31, 2012, respectively.
Schedule of reclassifications out of accumulated other comprehensive loss	'
	The following summarizes reclassifications out of Accumulated other comprehensive loss:
			Amount Reclassified from
			Accumulated Other Comprehensive Loss
	(dollars in millions)		Three Months Ended September 30, 2013			Nine Months Ended September 30, 2013			Line Item in the
									Condensed Consolidated
									Statement of Income (Loss)
	Impairment on marketable equity securities		$	0.4		$	3.5		Other expense, net
			—			—			Income tax benefit
	Net of income taxes		0.4			3.5
	Amortization of gain on terminated cash flow hedges		(0.1		)	(0.2		)	Other expense, net
			—			—			Income tax benefit
	Net of income taxes		(0.1		)	(0.2		)
	Amortization of pension plans actuarial losses		4.7			14.3			(1)
	Amortization of medical and dental plans actuarial losses		0.1			0.3			(1)
	Total before income taxes		4.8			14.6
			(1.9		)	(5.6		)	Income tax benefit
	Net of income taxes		2.9			9
	Total reclassifications for the period		$	3.2		$	12.3
	(1)	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Disclosure of basic and diluted earnings per share and effect of stock-based awards on the weighted average number of shares outstanding used in calculating diluted earnings per share	'
	The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating diluted earnings (loss) per share for the three and nine months ended September 30:
		Three Months Ended September 30,		Nine Months Ended September 30,
	(shares in millions)	2013	2012	2013	2012
	Weighted average basic common shares outstanding	165.7	165.1	165.5	165
	Incremental shares outstanding related to stock-based awards	1.3	0.8	—	1
	Weighted average dilutive common shares outstanding	167	165.9	165.5	166

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Weighted average fair value and weighted average assumptions utilized for option grants	'
	The weighted average grant date fair value using the Black-Scholes option-pricing model, and the corresponding weighted average assumptions for stock option grants for the three and nine months ended September 30, were as follows:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Volatility	31.5		%	31.3		%	30.3		%	31.3		%
	Expected life (years)	5.1			4.8			5.1			4.8
	Risk-free interest rate	1.3		%	0.7		%	0.9		%	0.8		%
	Dividend yield	0		%	0		%	0		%	0		%
	Fair value per stock option	$	11.77		$	9.15		$	8.48		$	10.01
Weighted fair value and weighted average assumptions for the performance share award grants	'
	The weighted average grant date fair value using the Monte Carlo simulation model and the corresponding weighted average assumptions for the annual performance share award grants, were as follows:
		2013			2012
	Volatility	30.8		%	27.3		%
	Risk-free interest rate	0.4		%	0.4		%
	Dividend yield	0		%	0		%
	Fair value per performance share	$	29.46		$	51.39
Weighted average fair value and weighted average assumptions utilized for performance based restricted stock units	'
	The weighted average grant date fair value using the Monte Carlo simulation model and the corresponding weighted average assumptions for the annual performance-based restricted stock units grants, were as follows:
		2013
	Volatility	30.2		%
	Risk-free interest rate	0.4		%
	Dividend yield	0		%
	Fair value per performance share	$	20.81

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]	'
Information about Hospira's reportable segments	'
	The table below presents information about Hospira’s reportable segments for the three months ended September 30:
		Net Sales				Income (Loss) from Operations
	(dollars in millions)	2013		2012		2013			2012
	Americas	$	804.2	$	789.1	$	75.7		$	34.3
	EMEA	123.5		122.9		(14.5		)	(28.0		)
	APAC	80.5		82		(1.5		)	6.9
	Total reportable segments	$	1,008.20	$	994	59.7			13.2
	Corporate functions					(19.5		)	(19.9		)
	Stock-based compensation					(10.4		)	(9.8		)
	Income (Loss) from operations					29.8			(16.5		)
	Interest expense and other expense, net					(62.3		)	(23.9		)
	Loss before income taxes					$	(32.5	)	$	(40.4	)
	The table below presents information about Hospira's reportable segments for the nine months ended September 30:
		Net Sales				(Loss) Income from Operations
	(dollars in millions)	2013		2012		2013			2012
	Americas	$	2,318.90	$	2,369.70	$	147.5		$	150.7
	EMEA	369.9		386.1		(73.5		)	(42.9		)
	APAC	229.6		237.4		(16.7		)	7.7
	Total reportable segments	$	2,918.40	$	2,993.20	57.3			115.5
	Corporate functions					(62.8		)	(57.6		)
	Stock-based compensation					(31.1		)	(29.9		)
	(Loss) Income from operations					(36.6		)	28
	Interest expense and other expense, net					(114.1		)	(77.1		)
	Loss before income taxes					$	(150.7	)	$	(49.1	)

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
In Millions, unless otherwise specified			Celltrion [Member]	Geographic Concentration Risk	Geographic Concentration Risk	Geographic Concentration Risk	API Busines [Member]
				Trade receivable	Trade receivable	Trade receivable
				Italy, Spain, Portugal and Greece	ITALY	SPAIN
Concentration of Credit Risk	'	'	'	'	'	'	'
Accounts Receivable, Gross	'	'	'	$114.20	'	'	'
Accounts Receivable, Net	'	'	'	107.9	41.7	52.1	'
Concentration Risk, Percentage	'	'	'	'	91.70%	93.60%	'
Supplier Advances	'	'	'	'	'	'	'
Cumulative advances to supplier	'	'	60	'	'	'	'
Period for additional supplier advances	'	'	'2 years	'	'	'	'
Advances to product suppliers	'	'	'	'	'	'	41.5
Total advances to product suppliers	$93.90	$92.90	'	'	'	'	'

Business_Acquisition_Details

Business Acquisition (Details) (API Busines [Member], USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013	Aug. 29, 2012
API Busines [Member]	'	'	'
Business Acquisition [Line Items]	'	'	'
Purchase price per agreement	'	'	$202.50
Revised approximate purchase price	218	218	'
Payment to acquire business	'	'	15
Acquisition and integration-related costs	1.2	3.9	'
Cumulative acquisition and integration-related costs	'	$5	'

Restructuring_Actions_Details

Restructuring Actions (Details) (USD $)	3 Months Ended		9 Months Ended				1 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Aug. 31, 2012	Sep. 30, 2012	Sep. 30, 2012	Sep. 30, 2012
				Other	Employee Severance [Member]	Contract Termination [Member]	Americas	Americas	Americas	Facilities Optimization [Member]
							Other	Other	Contract Termination [Member]	Americas
Restructuring Reserve	'	'	'	'	'	'	'	'	'	'
Asset impairment charges	'	'	'	'	'	'	'	$12.10	'	$17.40
Inventory charges	'	'	'	'	'	'	'	4.9	'	'
Restructuring costs incurred to date	'	'	'	'	11.4	3.1	'	'	0.9	'
Gain upon disposition of a non-strategic product line	'	'	'	'	'	'	1.9	'	'	'
Restructuring Charges	$3.10	$6.90	$7.60	$0	'	'	'	'	'	'

Restructuring_Actions_Details_

Restructuring Actions (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013
Restructuring Reserve [Roll Forward]	'	'	'
Balance at January 1, 2013	'	'	$7.10
Costs incurred	3.1	6.9	7.6
Payments	'	'	-7.5
Balance at September 30, 2013	7.2	7.1	7.2
Employee-Related Benefit Costs	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Balance at January 1, 2013	'	'	3.5
Costs incurred	'	'	7.6
Payments	'	'	-6
Balance at September 30, 2013	5.1	'	5.1
Other	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'
Balance at January 1, 2013	'	'	3.6
Costs incurred	'	'	0
Payments	'	'	1.5
Balance at September 30, 2013	$2.10	'	$2.10

Device_Strategy_Details

Device Strategy (Details) (Device Strategy [Member], USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Device Strategy and Related Costs [Line Items]	'	'
Expected non-cash charges	'	$60
Net Sales [Member]	'	'
Device Strategy and Related Costs [Line Items]	'	'
Charges incurred	'	104.3
Net Sales [Member] | Customer Sales Allowances [Member]	'	'
Device Strategy and Related Costs [Line Items]	'	'
Charges incurred	0	104.3
Cost of Products Sold [Member] | Contract Termination and Collection and Destruction [Member]	'	'
Device Strategy and Related Costs [Line Items]	'	'
Charges incurred	14.8	56.1
Cost of Products Sold [Member] | Inventory Charges [Member]	'	'
Device Strategy and Related Costs [Line Items]	'	'
Charges incurred	0.9	46.7
Restructuring and Impairment [Member] | Other Assets Impairment [Member]	'	'
Device Strategy and Related Costs [Line Items]	'	'
Charges incurred	3.2	10.3
Americas	'	'
Device Strategy and Related Costs [Line Items]	'	'
Charges incurred	18.9	217.4
Americas | Net Sales [Member]	'	'
Device Strategy and Related Costs [Line Items]	'	'
Charges incurred	'	88.4
Minimum	'	'
Device Strategy and Related Costs [Line Items]	'	'
Expected costs in connection with the Device Strategy	'	300
Estimated aggregate charges, cash	'	240
Maximum	'	'
Device Strategy and Related Costs [Line Items]	'	'
Expected costs in connection with the Device Strategy	'	350
Estimated aggregate charges, cash	'	$290

Collaborative_Arrangements_Det

Collaborative Arrangements (Details) (USD $)	3 Months Ended		9 Months Ended		3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Apr. 30, 2013
					NovaQuest [Member]	NovaQuest [Member]	Maximum
							NovaQuest [Member]
Schedule of Collaborative Arrangement Agreements [Line Items]	'	'	'	'	'	'	'
Minimum number of parties, active participans under collaborative arrangement	'	'	'2 or more	'	'	'	'
Development funding to be contributed	'	'	'	'	'	'	$150,000,000
Research and development expense	$69,900,000	$66,200,000	$218,100,000	$218,900,000	$22,100,000	$36,400,000	'

Investments_Details

Investments (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Combined income statement information of unconsolidated equity method investments	'	'	'	'
Revenue	$1,008,200,000	$994,000,000	$2,918,400,000	$2,993,200,000
Operating income	29,800,000	-16,500,000	-36,600,000	28,000,000
Net (loss) income	1,900,000	1,200,000	-41,800,000	38,900,000
Equity income from affiliates, net	2,700,000	6,900,000	12,700,000	27,000,000
Distributions received from equity affiliates	'	'	30,100,000	0
Zydus Hospira Oncology Private Limited	'	'	'	'
Combined income statement information of unconsolidated equity method investments	'	'	'	'
Ownership in a joint venture, Zydus Hospira Oncology Private Limited (as a percent)	50.00%	'	50.00%	'
Distributions received from equity affiliates	'	'	30,100,000	0
Unconsolidated equity method investments	'	'	'	'
Combined income statement information of unconsolidated equity method investments	'	'	'	'
Revenue	'	'	69,900,000	97,700,000
Operating expenses	'	'	33,300,000	25,100,000
Operating income	'	'	36,600,000	72,600,000
Net (loss) income	'	'	28,900,000	59,000,000
Equity and Cost Method Investments [Member]	'	'	'	'
Combined income statement information of unconsolidated equity method investments	'	'	'	'
Impairment on marketable equity securities, portion recognized in earnings, net	-2,700,000	'	-11,000,000	'
Cost-method Investments [Member]	'	'	'	'
Combined income statement information of unconsolidated equity method investments	'	'	'	'
Impairment on marketable equity securities, portion recognized in earnings, net	'	'	-8,400,000	'
Equity Securities [Member]	'	'	'	'
Combined income statement information of unconsolidated equity method investments	'	'	'	'
Impairment on marketable equity securities, portion recognized in earnings, net	$400,000	'	$3,500,000	'

Fair_Value_Measures_Details

Fair Value Measures (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Fair Value Assets and Liabilities Measurement	'	'
Senior unsecured notes, carrying value	$1,750	$1,700
Senior unsecured notes, fair value	1,864.70	1,865.70
Fair value	'	'
Fair Value Assets and Liabilities Measurement	'	'
Foreign currency forward exchange contracts, assets	1.2	0.6
Available-for-sale marketable equity securities	2.3	5.9
Foreign currency forward exchange contracts, liabilities	2.5	0.9
Quoted Prices in Active Markets for Identical Items (Level 1)	'	'
Fair Value Assets and Liabilities Measurement	'	'
Foreign currency forward exchange contracts, assets	0	0
Available-for-sale marketable equity securities	2.3	5.9
Foreign currency forward exchange contracts, liabilities	0	0
Significant Other Observable Inputs (Level 2)	'	'
Fair Value Assets and Liabilities Measurement	'	'
Foreign currency forward exchange contracts, assets	1.2	0.6
Available-for-sale marketable equity securities	0	0
Foreign currency forward exchange contracts, liabilities	2.5	0.9
Significant Unobservable Inputs (Level 3)	'	'
Fair Value Assets and Liabilities Measurement	'	'
Foreign currency forward exchange contracts, assets	0	0
Available-for-sale marketable equity securities	0	0
Foreign currency forward exchange contracts, liabilities	$0	$0

Financial_Instruments_and_Deri2

Financial Instruments and Derivatives (Details) (Derivatives not designated as hedging instruments, Foreign currency forward exchange contracts, USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Other receivables	'	'
Derivatives, Fair Value	'	'
Financial Assets	$1.20	$0.60
Other accrued liabilities	'	'
Derivatives, Fair Value	'	'
Financial Liabilities	$2.50	$0.90

Financial_Instruments_and_Deri3

Financial Instruments and Derivatives (Details 2) (Derivatives not designated as hedging instruments, Foreign currency forward exchange contracts, Other expense (income), net, USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Derivatives not designated as hedging instruments | Foreign currency forward exchange contracts | Other expense (income), net	'	'	'	'
Derivative Instruments, Loss (Gain)	'	'	'	'
Presentation of Loss (Gain) Recognized on Derivatives	($3)	($5.30)	$0	$1.10

Financial_Instruments_and_Deri4

Financial Instruments and Derivatives (Details 3) (Subsequent Event [Member], Foreign Exchange Option [Member], Designated as Hedging Instrument [Member])	Nov. 01, 2013	Nov. 01, 2013
	USD ($)	INR
Derivatives, Fair Value	'	'
Aggregate notional value	'	7,500,000,000
Net premium payable	$1,600,000	'

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Finished products	$428.60	$445.60
Work in process	320.7	262.2
Materials	322.1	290
Total inventories	1,071.40	997.8
Inventor Reserves	$144.50	$126.80

Property_and_equipment_net_Det

Property and equipment, net (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Property, Plant and Equipment [Abstract]	'	'
Property and equipment, at cost	$3,170	$3,067.50
Less: accumulated depreciation	-1,683	-1,622.40
Total property and equipment, net	$1,487	$1,445.10

Goodwill_and_Intangible_assets2

Goodwill and Intangible assets, net (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Goodwill	'	'	'	'
Goodwill balance at beginning of period	'	'	$1,079.10	'
Acquisitions	'	'	0	'
Goodwill impairments	'	'	0	'
Currency translation effect and other	'	'	-20.5	'
Goodwill balance at end of period	1,058.60	'	1,058.60	'
Intangible assets, net	'	'	'	'
Intangible assets balance at beginning of period	'	'	266.8	'
Additions of intangible assets	'	'	14.4	'
Amortization of intangible assets	-20.5	-20.5	-63.8	-62.6
Impairment of intangible assets	-5.2	'	-5.2	'
Intangible assets Currency translation effect and other, net	'	'	-20.2	'
Intangible assets balance at end of period	$192	'	$192	'

Goodwill_and_Intangible_assets3

Goodwill and Intangible assets, net (Details 2) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Intangible Assets:	'	'	'	'	'
Impairment of intangible assets	$5.20	'	$5.20	'	'
Weighted average useful life of intangible assets	'	'	'10 years	'	'
Finite-lived intangible assets, amortization expense	20.5	20.5	63.8	62.6	'
Estimated intangible asset amortization for 2013	22.5	'	22.5	'	'
Estimated intangible asset amortization for 2014	76.6	'	76.6	'	'
Estimated intangible asset amortization for 2015	52.4	'	52.4	'	'
Estimated intangible asset amortization for 2016	25.7	'	25.7	'	'
Estimated intangible asset amortization for 2017	15.7	'	15.7	'	'
Gross Carrying Amount	634.8	'	634.8	'	677.4
Accumulated Amortization	-442.8	'	-442.8	'	-410.6
Net Intangible Assets	192	'	192	'	266.8
IPR&D	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Gross Carrying Amount	2.1	'	2.1	'	3.8
Accumulated Amortization	0	'	0	'	0
Net Intangible Assets	2.1	'	2.1	'	3.8
Product rights and other	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Gross Carrying Amount	575.5	'	575.5	'	624.2
Accumulated Amortization	-413.9	'	-413.9	'	-389
Net Intangible Assets	161.6	'	161.6	'	235.2
Customer relationships	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Gross Carrying Amount	11.9	'	11.9	'	12.7
Accumulated Amortization	-7.5	'	-7.5	'	-6.8
Net Intangible Assets	4.4	'	4.4	'	5.9
Technology	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Gross Carrying Amount	45.3	'	45.3	'	36.7
Accumulated Amortization	-21.4	'	-21.4	'	-14.8
Net Intangible Assets	$23.90	'	$23.90	'	$21.90
Minimum	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Useful lives of intangible assets (in years)	'	'	'1 year	'	'
Maximum	'	'	'	'	'
Intangible Assets:	'	'	'	'	'
Useful lives of intangible assets (in years)	'	'	'16 years	'	'

Other_Assets_Details

Other Assets (Details) (USD $)	Sep. 30, 2013		Dec. 31, 2012
In Millions, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]	'		'
Supplier advances	$57.80		$72.80
Net investment in sales-type leases, less current portion	22.3	[1]	27.9	[1]
All other	69.3		67.9
Total	$149.40		$168.60
[1]	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

SalesType_Leases_Details

Sales-Type Leases (Details) (USD $)	9 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013		Dec. 31, 2012
Net investment in sales-type leases	'		'
Minimum lease payments receivable	$36.10		$44.10
Unearned interest income	-3.6		-5
Net investment in sales-type leases	32.5		39.1
Current portion	-10.2	[1]	-11.2	[1]
Net investment in sales-type leases, less current portion	$22.30	[1]	$27.90	[1]
Number of days amount past due in sales-type leases	'90 days		'90 days
[1]	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Accrued rebates	$145.60	$143.40
Income taxes payable	9.2	54.3
Product recall, customer sales allowances, customer accommodations and other related accruals	86.7	56.6
Accrued returns	20.4	21.7
All other	256.2	304.3
Total Other accrued liabilities	$518.10	$580.30

PostRetirement_Obligations_and2

Post-Retirement Obligations and Other Long-term Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]	'	'
Accrued post-retirement medical and dental costs	$49.50	$51.30
Pension liabilities	73.5	80.3
Unrecognized tax benefits, including penalties and interest	49.8	62
Product recall, customer sales allowances, customer accommodations and other related accruals	128	54.1
Accrued returns	10	7.1
All other	45.2	51.7
Total	$356	$306.50

Product_Recalls_Customer_Sales2

Product Recalls, Customer Sales Allowances, Customer Accomodations and Other Related Accruals (Textual) (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Millions, unless otherwise specified
Product recall and other related accruals	$214.70	$110.70
Device Strategy [Member]	'	'
Product recall and other related accruals	$137.70	'

Product_Recalls_Customer_Sales3

Product Recalls, Customer Sales Allowances, Customer Accomodations and Other Related Accruals (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013
Product Recalls and Related Accruals [Roll Forward]	'
Balance at beginning of period	$110.70
Provisions	138.2
Payments	-34.2
Balance at end of period	$214.70

Pension_and_PostRetirement_Ben2

Pension and Post-Retirement Benefits (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Defined Benefit Plan Disclosure	'	'	'	'
Defined contribution plan expenses	$11	$9.90	$32.10	$27.90
Pension Plans	'	'	'	'
Defined Benefit Plan Disclosure	'	'	'	'
Service cost for benefits earned during the period	0.4	0.3	1.1	1
Interest cost on projected benefit obligations	5.9	6	17.7	17.9
Expected return on plans' assets	-7.8	-8.1	-23.5	-24.2
Net amortization	4.7	4.7	14.3	14.1
Net cost	3.2	2.9	9.6	8.8
Medical and Dental Plans	'	'	'	'
Defined Benefit Plan Disclosure	'	'	'	'
Service cost for benefits earned during the period	0.1	0	0.2	0.1
Interest cost on projected benefit obligations	0.5	0.6	1.5	1.7
Net amortization	0.1	0.2	0.3	0.5
Net cost	$0.70	$0.80	$2	$2.30

Shortterm_Borrowings_and_Longt1

Short-term Borrowings and Long-term Debt (Details) (USD $)	1 Months Ended	9 Months Ended
	Aug. 31, 2013	Sep. 30, 2013	Sep. 30, 2012
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Payment on early debt extinguishment	'	$39,800,000	$0
Loss on early debt extinguishment	'	33,400,000	0
Unamortized debt discount	2,100,000	'	'
Underwriter's fees	6,100,000	'	'
Debt Covenants	'	'	'
Fees and expenses incurred	'	500,000	'
Unsecured Revolving Credit Facility Due October, 2016	'	'	'
Unsecured Revolving Credit Facility	'	'	'
Unsecured Revolving Credit Facility, maximum borrowing capacity	'	1,000,000,000	'
Availabilty for borrowings under the Revolver	'	541,000,000	'
Period Through March 31, 2013 Pre-amendment [Member]	'	'	'
Debt Covenants	'	'	'
Financial covenants, numerator for maximum leverage ratio	'	3.5	'
Financial covenants, denominator for maximum leverage ratio	'	1	'
Period March 31, 2013 through December 31, 2014 [Member]	'	'	'
Debt Covenants	'	'	'
Financial covenants, numerator for maximum leverage ratio	'	3.75	'
Financial covenants, denominator for maximum leverage ratio	'	1	'
Period January 1, 2015 and Thereafter [Member]	'	'	'
Debt Covenants	'	'	'
Financial covenants, numerator for maximum leverage ratio	'	3.5	'
Financial covenants, denominator for maximum leverage ratio	'	1	'
Senior Notes Due August 12, 2020 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Principal amount	350,000,000	'	'
Interest rate	5.20%	'	'
Senior Notes Due August 12, 2023 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Principal amount	350,000,000	'	'
Interest rate	5.80%	'	'
Senior Notes Due June 2014 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Interest rate	'	5.90%	'
Amount of debt extinguished	'	400,000,000	'
Senior Notes Due May 2015 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Interest rate	'	6.40%	'
Amount of debt extinguished	'	250,000,000	'
Senior Notes 2014 and 2015 [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Payment on early debt extinguishment	'	39,800,000	'
Loss on early debt extinguishment	'	33,400,000	'
Interest Rate Swap [Member]	'	'	'
Long-term and Short-term Debt Instruments [Line Items]	'	'	'
Derivative, notional amount terminated	550,000,000	'	'
Swap termination charges and interest	$3,600,000	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'
Unrecognized tax benefits, estimated future decreases resulting from settlements with taxing authorities in next fiscal year	'	$10
Payment to finalize 2008 and 2009 federal tax audit	$53.10	'

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	1 Months Ended	9 Months Ended
	Apr. 30, 2011	Sep. 30, 2013	Dec. 31, 2012
Common and Preferred Stock	'	'	'
Common Stock, Shares Authorized	'	400,000,000	'
Common Stock, Par Value Per Share (in dollars per share)	'	$0.01	'
Preferred Stock, Shares Authorized	'	50,000,000	'
Preferred Stock, Par Value Per Share (in dollars per share)	'	$0.01	'
Common Stock, Shares Issued	'	179,000,000	178,400,000
Common Stock, Shares Outstanding	'	165,900,000	165,300,000
Treasury Stock	'	'	'
Treasury Stock, repurchase authorization (in dollars)	$1,000,000,000	$0	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive (Loss) Income, net of tax (Details) (USD $)	3 Months Ended			9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013		Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2012	Dec. 31, 2012
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'	'		'	'
Balance at January 1, 2013	'		'	($83.20)		'	'
Other comprehensive loss before reclassifications	'		'	-145		'	'
Amounts reclassified from accumulated other comprehensive loss	'		'	12.3		'	'
Balance at September 30, 2013	-215.9		'	-215.9		'	'
Cumulative foreign currency translation adjustments, tax	0		'	0		'	48.1
Cumulative retirement plans unrealized losses, tax	73		'	73		'	78.6
Cumulative unrealized gains on marketable equity securities, tax	-1		'	-1		'	-0.4
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'	'		'	'
Income tax (benefit) expense	31.7		34.7	96.2		61	'
Net Income (Loss)	1.9		1.2	-41.8		38.9	'
Cumulative Foreign Currency Translation Adjustments	'		'	'		'	'
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'	'		'	'
Balance at January 1, 2013	'		'	48.1	[1]	'	'
Other comprehensive loss before reclassifications	'		'	-139.3	[1]	'	'
Amounts reclassified from accumulated other comprehensive loss	'		'	0	[1]	'	'
Balance at September 30, 2013	-91.2	[1]	'	-91.2	[1]	'	'
Cumulative Retirement Plans Unrealized Losses	'		'	'		'	'
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'	'		'	'
Balance at January 1, 2013	'		'	-132.4	[2]	'	'
Other comprehensive loss before reclassifications	'		'	0	[2]	'	'
Amounts reclassified from accumulated other comprehensive loss	'		'	9	[2]	'	'
Balance at September 30, 2013	-123.4	[2]	'	-123.4	[2]	'	'
Cumulative Unrealized Gains on Marketable Equity Securities	'		'	'		'	'
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'	'		'	'
Balance at January 1, 2013	'		'	0.4	[1]	'	'
Other comprehensive loss before reclassifications	'		'	-3.5	[1]	'	'
Amounts reclassified from accumulated other comprehensive loss	'		'	3.5	[1]	'	'
Balance at September 30, 2013	0.4	[1]	'	0.4	[1]	'	'
Cumulative Gains on Terminated Cash Flow Hedges	'		'	'		'	'
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]	'		'	'		'	'
Balance at January 1, 2013	'		'	0.7	[3]	'	'
Other comprehensive loss before reclassifications	'		'	-2.2	[3]	'	'
Amounts reclassified from accumulated other comprehensive loss	'		'	-0.2	[3]	'	'
Balance at September 30, 2013	-1.7	[3]	'	-1.7	[3]	'	'
Reclassification out of Accumulated Other Comprehensive Income [Member]	'		'	'		'	'
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'	'		'	'
Net Income (Loss)	3.2		'	12.3		'	'
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cumulative Retirement Plans Unrealized Losses	'		'	'		'	'
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'	'		'	'
Income tax (benefit) expense	-1.9		'	-5.6		'	'
Amortization of pension plans actuarial losses	4.7	[4]	'	14.3	[4]	'	'
Amortization of medical and dental plans actuarial losses	0.1	[4]	'	0.3		'	'
Total before income taxes	4.8		'	14.6		'	'
Net Income (Loss)	2.9		'	9		'	'
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cumulative Unrealized Gains on Marketable Equity Securities	'		'	'		'	'
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'	'		'	'
Impairment on marketable equity securities, portion recognized in earnings, net	0.4		'	3.5		'	'
Income tax (benefit) expense	0		'	0		'	'
Net Income (Loss)	0.4		'	3.5		'	'
Reclassification out of Accumulated Other Comprehensive Income [Member] | Cumulative Gains on Terminated Cash Flow Hedges	'		'	'		'	'
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]	'		'	'		'	'
Income tax (benefit) expense	0		'	0		'	'
Amortization of gain on terminal cash flow hedges	0.1		'	0.2		'	'
Net Income (Loss)	($0.10)		'	($0.20)		'	'
[1]	Net of taxes of $0.0 million as of SeptemberB 30, 2013 and DecemberB 31, 2012.
[2]	Net of taxes of $73.0 million and $78.6 million as of SeptemberB 30, 2013 and DecemberB 31, 2012, respectively
[3]	Net of taxes of $(1.0) million and $(0.4) million as of SeptemberB 30, 2013 and DecemberB 31, 2012, respectively.
[4]	These accumulated other comprehensive loss components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_Per_Share_Details

Earnings Per Share (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Weighted average basic common shares outstanding	165,700,000	165,100,000	165,500,000	165,000,000
Incremental shares outstanding related to stock-based awards	1,300,000	800,000	0	1,000,000
Weighted average dilutive common shares outstanding	167,000,000	165,900,000	165,500,000	166,000,000
Outstanding Stock Awards [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Incremental common shares related to stock-based awards excluded from computation of earnings per share because of the net loss and the awards related anti-dillutive effect	'	'	1,000,000	'
Outstanding options with exercise price of the options exceeding the average stock price (in shares)	8,200,000	9,800,000	8,500,000	9,400,000

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award	'	'	'	'
Stock-based compensation expense	$10.40	$9.80	$31.10	$29.90
Income tax benefit related to stock-based compensation	3.8	3.6	11.4	10.4
Unrecognized compensation costs related to non-vested share-based compensation arrangements	$80.70	'	$80.70	'
Period over which unrecognized compensation cost is expected to be recognized (in years)	'2 years 7 months 18 days	'	'	'
Performance Based Restricted Stock Units	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'	'	'
Granted (in shares)	200,000	'	'	'
Term	'	'	'3 years	'
Appreciation on fair value, percentage	'	'	120.00%	'
Appreciation level period	'	'	'30 days	'
Stock option award	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award	'	'	'	'
Stock Options Granted	'	'	1,800,000	'
Vesting period, low end of range (in years)	'	'	'4 years	'
Term	'	'	'7 years	'

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Stock option award	'	'	'	'
Weighted average fair value and weighted average assumptions	'	'	'	'
Volatility	31.50%	31.30%	30.30%	31.30%
Expected life (in years)	'5 years 1 month 6 days	'4 years 9 months 18 days	'5 years 1 month 6 days	'4 years 9 months 18 days
Risk-free interest rate	1.30%	0.70%	0.90%	0.80%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Fair value per stock option	$11.77	$9.15	$8.48	$10.01
Restricted Stock and Performance Share Awards	'	'	'	'
Vesting period, low end of range (in years)	'	'	'4 years	'
Term	'	'	'7 years	'
Performance stock awards	'	'	'	'
Weighted average fair value and weighted average assumptions	'	'	'	'
Volatility	'	'	30.80%	27.30%
Risk-free interest rate	'	'	0.40%	0.40%
Dividend yield	'	'	0.00%	0.00%
Fair value per stock option	'	'	$29.46	$51.39
Restricted Stock and Performance Share Awards	'	'	'	'
Granted (in shares)	'	'	200,000	'
Performance cycle (in years)	'	'	'3 years	'
Performance share awards earned, low end of the range (as a percent)	'	'	0.00%	'
Performance share awards earned, high end of the range (as a percent)	'	'	200.00%	'
Performance Based Restricted Stock Units	'	'	'	'
Weighted average fair value and weighted average assumptions	'	'	'	'
Volatility	'	'	30.20%	'
Risk-free interest rate	'	'	0.40%	'
Dividend yield	'	'	0.00%	'
Fair value per stock option	'	'	$20.81	'
Restricted Stock and Performance Share Awards	'	'	'	'
Granted (in shares)	200,000	'	'	'
Term	'	'	'3 years	'
Restricted stock awards	'	'	'	'
Restricted Stock and Performance Share Awards	'	'	'	'
Granted (in shares)	'	'	1,100,000	'
Weighted average grant date fair value, at the end of the period (in dollars per share)	$29	'	$29	'
Minimum | Restricted stock awards	'	'	'	'
Restricted Stock and Performance Share Awards	'	'	'	'
Vesting period, low end of range (in years)	'	'	'1 year	'
Maximum | Restricted stock awards	'	'	'	'
Restricted Stock and Performance Share Awards	'	'	'	'
Vesting period, low end of range (in years)	'	'	'3 years	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	Sep. 30, 2013
	Lawsuit
Derivative lawsuits	'
Loss Contingencies	'
Number of shareholders	2
Precedex	'
Loss Contingencies	'
Pending cases against other company	2

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
	Segment
	units
Segment Reporting Information	'	'	'	'
Net Sales	$1,008.20	$994	$2,918.40	$2,993.20
Stock-based compensation	-10.4	-9.8	-31.1	-29.9
(Loss) Income From Operations	29.8	-16.5	-36.6	28
Interest expense and other expense (income), net	-62.3	-23.9	-114.1	-77.1
Loss Before Income Taxes	-32.5	-40.4	-150.7	-49.1
Reportable segments number	3	'	'	'
Operating units number	6	'	'	'
Reportable segments	'	'	'	'
Segment Reporting Information	'	'	'	'
(Loss) Income From Operations	59.7	13.2	57.3	115.5
Americas	'	'	'	'
Segment Reporting Information	'	'	'	'
Net Sales	804.2	789.1	2,318.90	2,369.70
(Loss) Income From Operations	75.7	34.3	147.5	150.7
EMEA	'	'	'	'
Segment Reporting Information	'	'	'	'
Net Sales	123.5	122.9	369.9	386.1
(Loss) Income From Operations	-14.5	-28	-73.5	-42.9
APAC	'	'	'	'
Segment Reporting Information	'	'	'	'
Net Sales	80.5	82	229.6	237.4
(Loss) Income From Operations	-1.5	6.9	-16.7	7.7
Corporate functions	'	'	'	'
Segment Reporting Information	'	'	'	'
(Loss) Income From Operations	-19.5	-19.9	-62.8	-57.6
Device Strategy [Member] | Americas	'	'	'	'
Segment Reporting Information	'	'	'	'
Charges incurred	18.9	'	217.4	'
Device Strategy [Member] | Net Sales [Member]	'	'	'	'
Segment Reporting Information	'	'	'	'
Charges incurred	'	'	104.3	'
Device Strategy [Member] | Net Sales [Member] | Americas	'	'	'	'
Segment Reporting Information	'	'	'	'
Charges incurred	'	'	88.4	'
Device Strategy [Member] | Net Sales [Member] | EMEA	'	'	'	'
Segment Reporting Information	'	'	'	'
Charges incurred	'	'	13.2	'
Device Strategy [Member] | Net Sales [Member] | APAC	'	'	'	'
Segment Reporting Information	'	'	'	'
Charges incurred	'	'	$2.70	'